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Welcome
15th Annual International Meeting of the Institute of Human 
Virology, in partnership with the Global Virus Network and the 
Moscow Center for HIV/AIDS Treatment and Prevention
Dear Colleagues and Friends,
The Institute of Human Virology (IHV) at the University of 
Maryland School of Medicine, the Global Virus Network 
(GVN), and the Moscow Center for HIV/AIDS Treatment 
and Prevention welcome you to the Institute’s 15th 
Annual International Meeting. For only the second time 
in IHV’s history, the meeting is convening outside of the 
Baltimore/Washington DC area. This year we gather in 
Moscow, a city obviously of deep historical significance 
and home to stunning architecture, cultural tradition, and 
the Russian Federation Capitol. Further, uniquely this year, 
the meeting will include presentations from members of 
the Global Virus Network, thereby broadening the scope 
of the meeting. The IHV Annual Meeting has fostered 
international scientific cooperation since its inception. 
This year’s event recognizes both our commitment to the 
global fight against HIV/AIDS as well as a focus on several 
other human viral diseases, and the critical roles played 
by the scientists, physicians, and public health officials in 
the Russian Federation. We are pleased to join together 
for hosting this meeting and believe it will impact the 
future of research on viral diseases in our countries and 
throughout our network of collaborating institutions. 
This year’s open meeting is from Sunday, September 8 
through Wednesday, September 12.  An outstanding 
program of Russian and international experts in medical 
virology will be presented in the Moscow City Meeting 
Hall. While our major focus continues to be in HIV/AIDS, 
through the Global Virus Network, we will expand the 
scope to cover other important human viral diseases 
including hepatitis, measles, influenza, enterovirus, polio   
and hemorrhagic fever. For each, we concentrate on the 
latest developments in antiviral drug treatment or 
preventive vaccines; we also address the roles for viruses in 
human cancer, how they cause diseases and how they are 
spread. Workshops provide practical lessons for managing 
co-morbidities of HIV/AIDS including hepatitis, cancer, 
tuberculosis and diabetes. Truly, this meeting combines the 
best knowledge on diagnosis, treatment and prevention 
of human viral diseases and will be an important event. 
We look forward to you joining us in beautiful Moscow 
to explore the most recent and important developments 
in HIV/AIDS research and other viral diseases and to 
acknowledge the progress and challenges in global 
health research.
Sincerely,
    Robert C. Gallo, MD
    Director and Professor
    Institute of Human Virology and
    Co-founder & Scientific Director of the
    Global Virus Network (GVN)
    Alexey Mazus, MD
  Head
    Moscow Center for HIV/AIDS Prevention  
  and  Treatment
    Sharon Hrynkow, PhD
  President
    Global Virus Network (GVN)
  
    C. David Pauza, PhD
    Associate Director and Professor
    Institute of Human Virology
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Mission Statement
The Institute of Human Virology (IHV) is a world-class center of excellence focusing on chronic viral diseases and 
virally linked cancers. IHV is dedicated to biomedical research leading to improved treatment and prevention of 
these diseases.
 
Our unique structure connects cohesive, multidisciplinary research and clinical programs so that new treatments 
are streamlined from discovery to patients. IHV is forging local and international programs for research and 
treatment of human disease.
The IHV is also a Center of Excellence in the Global Virus Network (GVN), and this year’s meeting in Moscow 
will be immediately followed by a shorter GVN meeting.  GVN President, Sharon Hrynkow, is the meeting 
coordinator with Professor Alexey Mazus.
The mission of the Global Virus Network is to strengthen medical research and response to current viral causes 
of human disease and to prepare against new viral pandemic threats.
The Moscow Center for HIV/AIDS Prevention and Treatment (AIDS Center) of the Moscow Health Department 
is the main unit of the city service providing HIV prevention and medical treatment services for Moscow citizens 
living with HIV/AIDS.
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Global Virus Network - Centers Of Excellence
AFRICA
•	 South African National Institute for Communicable Diseases (NICD), Division of National Health Laboratory 
Service (NHLS), Janusz Paweska, BVSC, DVSC*, Robert Swanepoel, BVSC, DTVM, PhD
AUSTRALIA
•	 The Peter Doherty Institute (Melbourne), James McCluskey, MD, PhD, MPH*, Anne Kelso, PhD
ASIA
•	 China Centers for Disease Control, China, Yi Zeng, MD, PhD*
•	 National Institute of Infectious Diseases (NIID-Tokyo), Japan, Hideki Hasegawa, MD,PhD
•	 Amrita Institute of Medical Sciences, India, Prem Nair, MD 
EURASIA
•	 Moscow Center for AIDS Prevention, Russia, Alexey Mazus, MD
•	 Mechinov Institute of Vaccines & Sera, Russia, Vitaly V. Zverev, PhD,
•	 Chumakov Institute of Poliomyelitis & Viral Encephalitides, Russia, Alexander Lukashev, PhD*
EUROPE
•	 University College Dublin, Ireland, William Hall, PhD*
•	 Autonomous University of Madrid, Spain, Esteban Domingo, PhD, Luis Menendez-Arias, PhD
•	 Ernst Schering Foundation, Germany, Reinhard Kurth, MD*, Robert Koch Institute, Germany, Reinhard 
Burger, PhD, Technical University of Munich, Germany, Ulrike Protzer, MD, Philipp University Marburg, 
Germany, Stephan Becker, PhD
•	 University of Padua, Italy, Luigi Chieco-Bianchi, MD, PhD, University of Milano, Italy, Guido Poli, MD, PhD, 
University of Naples-Nat’l Cancer Institute, Italy, Franco Buonaguro, MD, Luigi Buonaguro, MD, Veterinary 
Public Health Institute (IZSVe), Italy, Ilaria Capua, DVM, PhD
•	 University of Glasgow, Scotland, United Kingdom, Massimo Palmarini, DVM, PhD, FRSE
•	 Karolinska Institute, Sweden-Baltic, Anders Vahlne, MD, PhD
•	 Gembloux Agro-Biotech, Northern Europe, Arsène Burny, PhD
MIDDLE EAST
•	 Tel Aviv University, Israel, Jonathan Gershoni, PhD
SOUTH AMERICA
•	 National University of La Plata, Argentina, Victor Romanowski, PhD*
NORTH AMERICA/USA
•	 Institute of Human Virology at the University of Maryland, Robert Gallo, MD*, Maria Salvato, PhD, C. David 
Pauza, PhD, William Blattner, MD, Robert Redfield, MD
•	 Gladstone Institute, University of California San Francisco, Warner Greene, MD, PhD, Eric Verdin, MD
•	 Johns Hopkins University, Maryland, Diane Griffin, MD, PhD
•	 University of Michigan, Mark Kaplan, MD, FACP
•	 University of Texas Medical Branch-Galveston National Labs, James LeDuc, PhD
•	 The Scripps Research Institute, California, Michael Oldstone, MD, Erica Saphire, PhD
•	 Mt. Sinai School of Medicine, New York, Peter Palese, PhD*, Adolfo Garcia-Sastre, PhD
•	 J. Craig Venter Institute, Maryland, David Wentworth, PhD, John Glass, PhD
•	 University of Pittsburgh, Pennsylvania, Patrick Moore, MD, MHP and Yuan Chang,
•	 University of Rochester, New York, John Treanor, MD, David Topham, PhD 
*Member of the GVN Scientific Leadership Board
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Moscow Center for HIV/AIDS Prevention and Treatment
The Moscow Center for HIV/AIDS Prevention and Treatment (AIDS Center) of the Moscow Health Department 
is the main unit of the city service providing HIV prevention and medical treatment services for Moscow citizens 
living with HIV/AIDS. The center was established based on a department of the Clinical Hospital No. 2 for 
Infectious Diseases which, since 1985, had started receiving first individuals in the Soviet Union identified as 
HIV/AIDS positive.
The specialists who provided medical treatment to the first HIV/AIDS positive individuals formed the backbone 
of the AIDS Center team. Today it employs more than 200 people working in its 7 departments. The AIDS 
Center receives patients from healthcare institutions who need their HIV-positive diagnosis to be confirmed and 
be further registered with the Center or those with controversial HIV antibody test results. The Center provides 
all types of specialist medical treatment to the HIV/AIDS positive people. Patients and their relatives can get 
consulting, methodological and psychological assistance as well.
The major success of the Center has been the implementation in Moscow medical institutions of a program 
to reduce the risk of a vertical transmission from an HIV-positive mother to her child during pregnancy and 
birth. It comes to be of particular relevance today when increasing numbers of HIV-positive women decide to 
have children. The implementation of special innovative prevention programs has lead to more than a six-fold 
reduction in the probability of an HIV-positive child birth which is now less than 3 percent.
The Center contributes to scientific research, as well as approves and implements new methods of HIV diagnosis 
and treatment. The AIDS Center coordinates HIV prevention efforts of all Moscow medical facilities and monitors 
the quality of HIV laboratory diagnosis in Moscow healthcare institutions.
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The Institute of Human Virology at the University of Maryland School of Medicine is grateful for the assistance 
provided by our International Organizing Committee
C. David Pauza
Institute of Human Virology
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Yiming Shao 
Chinese Center for Disease Control 
and Prevention
Beijing, China
Guido Poli
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Leonid Margolis
National Institutes of Health
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Weill Cornell Medical College
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Communications and Press Policy
To enhance the exchange of information and communication among attendees of the Institute of Human 
Virology Annual International Meeting, in partnership with the Global Virus Network and Moscow, the following 
must be adhered to by all participants:
•	 All comments at sessions are off-the-record and are not for attribution.
•	 No coverage, reporting or publication of scientific data or presentations at the Institute of Human Virology 
Annual Meeting is permitted without the written consent of the presenter(s) and Nora Grannell (info below). 
This rule applies to all forms of media, including blogging.
One-on-one interviews with scientists and media may be arranged by contacting Nora Grannell, Director of 
Public Relations and Marketing, Institute of Human Virology, (410) 706-1954 or ngrannell@ihv.umaryland.edu.
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IHV 2013 Lifetime Achievement Award for  
Scientific Contributions
Vadim I. Agol, MD, PhD, DSc
Vadim I. Agol is a, if not the, number one polio virologist in the world in terms 
of the basic science of these viruses. He received an MD diploma cum laude 
from the 1st Moscow Medical School in 1951 and worked for 5 years at the 
Karaganda Medical Institute. In 1956 he joined the Institute for Poliomyelitis 
Research in Moscow (now M. P. Chumakov Institute of Poliomyelitis and Viral 
Encephalitides of the Russian Academy of Medical Sciences) as junior researcher 
and has been associated with this Institute until now (from 1957 as senior 
researcher, in 1961-2009 as head of Laboratory of Biochemistry, and now as 
chief researcher at this lab). He received a PhD in 1954 from the first Moscow 
Medical School and DSc in 1967 from the USSR Academy of Medical Sciences. 
In 1963 he participated in the organization of the Department of Virology of 
the Moscow State University, serving there as Docent and in 1969-2012 as 
Professor. He also established and continues as head of the Department of 
Virus/Cell Interactions at the Institute of Physical-Chemical Biology of the  
same University.
His main scientific interests are focused on diverse aspects of molecular and 
cellular biology of RNA-containing viruses (primarily picornaviruses) such 
as non-genetic and genetic interactions (co-discovery of complementation 
between non-enveloped RNA viruses; first biochemical proof of the 
intermolecular recombination between RNA genomes; demonstration of the existence of the non-replicative mechanism 
of this process), synthesis of viral proteins (first cell-free system for the faithful translation of picornavirus proteins; 
structural and functional analysis of translational cis-acting element of picornaviral RNAs; discovery and characterization of 
non-canonical translation initiation factors required for the synthesis of picornaviral proteins; identification of a protease 
involved in processing of the viral polyprotein; discovery of picornaviral leader proteins; first translational mapping of the 
flavivirus genome), replication of viral RNA (first evidence for involvement of host proteins in the synthesis of picornavirus 
RNA; characterization of viral 2C protein involved in the viral replication; functional and structural characterization of 
replicative cis-elements of the picornavirus genomes), neurovirulence and attenuation of picornaviruses (first mapping 
of viral phenotypic traits by recombinational analysis; discovery of dependence of attenuation on modulation of viral 
translation), cellular response to picornaviral infection (discovery of the ability of picornaviruses to trigger and suppress 
apoptotic response of the cells; discovery of the ability of picornaviruses to permeabilize the nuclear envelope by different 
mechanisms; demonstration that major picornavirus-induced cellular damages may be caused by interplay between host 
defense and viral anti-defenses and may be uncoupled from viral reproduction; proposal on the existence of a distinct 
set of viral proteins, dubbed security proteins, specifically dedicated to the anti-defensive activities), evolution (roles of 
changes in attenuation determinants, antigenic properties and recombination in the evolution of vaccine polioviruses; 
molecular epidemiology of poliomyelitis). He actively participated in the world struggle against polio.
Dr. Agol is an (elected) corresponding member of the Russian Academy of Sciences and Russian Academy of Medical 
Sciences, Honorary Scientist of Russia, recipient of the Triumph prize in biology and medicine, foreign member of the 
Bulgarian Academy of Sciences, and also received other national and international awards.
Apart from numerous scientific publications, Dr. Agol has published four books of poetry and a book containing an 
autobiographical novel of his father, well known Soviet geneticist and philosopher Israel Agol, and his own autobiography.
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IHV 2013 IHV Lifetime Achievement Award for  
Public Service
José Esparza, MD, PhD
José Esparza is an internationally recognized expert on HIV/AIDS, vaccine 
development and global health. His overall mission has been to harness science 
to address global health problems, focusing on the discovery, development 
and delivery of vaccines. No one has done more to advance HIV vaccine 
development. 
Since 2004 he has been with the Bill & Melinda Gates Foundation in Seattle, 
WA first as Senior Advisor on HIV Vaccines and currently as Senior Advisor 
on Vaccines. In 2012 he was appointed Adjunct Professor of Medicine at the 
Institute of Human Virology, University of Maryland School of Medicine. 
Previously in 1986, he joined the World Health Organization (WHO) in Geneva, 
Switzerland, to work on viral diseases with epidemic potential. When WHO 
launched its Global Program on AIDS (GPA) in 1987, Esparza established and led 
its Biomedical Research Unit. Later he became the Chief of the WHO/GPA Vaccine 
Development Unit. In 1996 he transitioned to the newly established United 
Nations Program on HIV/AIDS –UNAIDS (Geneva, Switzerland) as Coordinator 
of the WHO-UNAIDS HIV Vaccine Initiative. He became a recognized global 
leader in the field of HIV vaccines.
From 1974 to 1985 he worked in Caracas, Venezuela, at the Venezuelan Institute 
of Scientific Research – IVIC, at that time, one of the most important research 
institutions in Latin America. He served as Professor of Virology, Head of the 
Laboratory of Biology of Viruses and Chairman of the Center of Microbiology 
and Cell Biology. During this time he published extensively on rotaviruses 
associated with gastroenteritis. 
He is the author of over 175 papers on different aspects of virology, HIV/
AIDS and vaccine development. Esparza has served in numerous national and 
international scientific advisory committees and boards, receiving numerous 
awards in recognition to his many contributions to global health. He is a member 
of the National Academy of Medicine of Venezuela and of the Royal Academy 
of Doctors of Spain.
He received his MD degree in his native country of Venezuela (1968) and a PhD 
in Virology and Cell Biology from Baylor College of Medicine in Houston, TX 
(1974). 
He currently lives with his wife in Seattle, WA and has a daughter and grandson.
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Previous Recipients of IHV Lifetime  
Achievement Awards
IHV Lifetime Achievement Award for Scientific Contributions
1999  George Klein, Karolinska Institute, Stockholm, Sweden
2000  Maurice Hilleman, Merck Research Laboratories, Sumneytown, Pennsylvania
2001  Hilary Koprowski, Thomas Jefferson University, Philadelphia, Pennsylvania
2002  Alexander Rich, Massachusetts Institute of Technology, Cambridge, Massachusetts
2003  Jan Svoboda, Institute of Molecular Genetics, Prague, Czech Republic
2004  Paul Zamecnik, Massachusetts General Hospital, Boston, Massachusetts
2005  Manfred Eigen, Max Planck Institute, Göttingen, Germany
2006  Maxine Singer, National Institutes of Health, Bethesda, Maryland
2008  Isaac P. Witz, Tel Aviv University, Tel Aviv, Israel
2010  Dr. Rino Rappuoli, Novartis Vaccines in Sienna, Italy
2011    Max Essex, Harvard AIDS Institute
2012    Thomas A Waldmann, MD, NIH
IHV Lifetime Achievement Award for Public Service
2004  Stewart Greenebaum, Greenebaum and Rose Associates, Inc., Baltimore, Maryland
2006  Martin Delaney, Project Inform, San Francisco, California
2008  John D. Evans, Evans Telecommunication Company and  
  The Honorable Robert K. Gray, Gray and Company II, Miami, FL
2010  Harry Huge, Esq.
2011   Bernadine Healy, MD, NIH
2011   Yi Zeng, PhD, China CDC  
One-Time IHV Lifetime Achievement Award for Excellence in Teaching
2010 Michele LaPlaca, Bologna, Italy
IHV Lifetime Achievement Award for Excellence in Medical Education, Clinical Care and  
Clinical Research
2012    John G. Bartlett, MD Johns Hopkins School of Medicine
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Program Overview    
Sunday, September 8, 2013
    9:00 – 10:00    Registration of participants
 
  10:00 – 13:00    Track: Advances in Vaccine Research (I)
      Conference Hall Sector B+C
  13:00 – 14:00    Lunch
 
  14:00 – 17:45    Track: Advances in Vaccine Research (II)
      Conference Hall Sector B+C
Monday, September 9, 2013
    9:00 –   9:30    Registration of participants
  10:00 – 12:00     Track: Advances in Antiviral Drug Discovery (I)
      Grand  Conference-Hall
  12:00 – 13:00    Lunch
 
  13:00 – 14:00    Official Opening Ceremony of the Conference
      Grand  Conference-Hall
  14:00 – 15:00    Public Lecture by Dr. Robert C. Gallo
      Grand  Conference-Hall
  15:00 – 16:30    Track: Advances in Antiviral Drug Discovery (II)
      Grand  Conference-Hall
  16:30 – 17:00     Presentation of IHV Lifetime Achievement      
          Awards to Vadim I. Agol and José Esparza
      Grand  Conference-Hall
  17:00 – 17:30     Lecture in Honor of the Recipients of  
          the IHV Lifetime Achievement Award
      Grand  Conference-Hall
  19:30 – 21:00    Awards Gala Banquet 
      Yar  Restaurant
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Program Overview    
Tuesday, September 10, 2013
    9:00 – 12:15    Track: Mechanisms of Viral Pathogenesis
      Conference Hall Sector B+C
  12:15 – 13:30    Lunch
 
  13:30 – 17:00    Track: Mechanisms for Virus Transmission
      Conference Hall Sector B+C
  14:00 – 16:00    Public Lectures by 
          John G. Bartlett and Robert R. Redfield
      Moscow State University of Medicine and  
      Dentistry  named  after  A.I.Evdokimov
  16:00 – 17:30    Public Lectures by 
          G. Steven Burrill and Robert C. Gallo
      I.M. Sechenov First Moscow State  
      Medical  University
               18:00    Adjourn
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Wednesday, September 11, 2013
    9:00 – 12:00    Track: Viruses and Cancer
      Conference Hall Sector B+C
  12:00 – 14.00    Lunch
  14:00 – 18:00    Track: Clinical Management of Co-Morbidities  
      in  HIV/AIDS
      Conference Hall Sector B+C
  19:00 – 21:00    Opening Dinner of the Global Virus Network
          Keynote Speaker: G. Steven Burrill
      Chairman,  Global  Virus  Network
      Russian Academy of Medical Sciences
By Invitation Only:
  14:30 – 18:30      GVN Meeting, Conference Hall, Sector T
               19:30    Welcome Dinner of the GVN
          Keynote Speaker:  G. Steven Burrill
      Chairman,  Global  Virus  Network
          Russian Academy of Medical Sciences 
 
Thursday, September 12, 2013
GVN Meeting (closed) and Moscow International Virology Week Sessions15th Annual International Meeting of the Institute of Human Virology 19
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Speaker Schedule
Sunday, September 8, 2013
Conference-Hall Sector B+C    
9:00 - 10:00    Registration
 
10:00 - 13:00  Advances in Vaccine Research (I) 
 
Chairs: R.M.Khaitov, member of the Russian Academy of Sciences and Russian Academy of Medical Sciences, 
M.D., Professor, Director of the National Research Centre Institute of Immunology, Federal Medical and 
Biological Agency of Russia, 
N.A.Malyshev, M.D., Professor, Chief Physician of Clinical Hospital for Infectious Diseases No.1 of the Moscow 
Health Department, Russia      
 
KEYNOTE PRESENTATION: 
E.V.Karamov, R.M.Khaitov
National Research Centre Institute of Immunology, FMBA of Russia
101 - Biomedical Prevention of HIV/AIDS in Russia (30 min.)
G.O. Gudima
National Research Centre Institute of Immunology, FMBA of Russia 
102 - HIV/AIDS Vaccines in Russia: Clinical Trials and Estimation of Acceptance in Population (20 min.)
I.A.Kofiadi
National Research Centre Institute of Immunology, FMBA of Russia 
103 - Genetic Factors Defining Resistance and Susceptibility to HIV/AIDS (20 min.)
A.V.Filatov, D.V.Mazurov 
National Research Centre Institute of Immunology, FMBA of Russia 
104 - Cell-to-cell Transmission of HIV-1: Role of Virological Synapse (15 min.)
11:25 - 11:40  Break
I.A.Nikolaeva
National Research Centre Institute of Immunology, FMBA of Russia 
105 - Rationale for HIV/AIDS Vaccines Design (20 min.)
R.I.Ataullakhanov
National Research Centre Institute of Immunology, FMBA of Russia 
106 - Enhance Expression of Transgene in Adenovirus (15 min.)
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S.V.Korobova
National Research Centre Institute of Immunology, FMBA of Russia 
107 - The Modern Methods of HIV/AIDS Vaccine Evaluation (15 min.)
M.M.Shmarov
Gamaleya Scientific Research Institute of Epidemiology and Microbiology of the Health Ministry of the  
Russian Federation
108 - Development of Universal Vaccines against Flu (15 min.)
A.V.Tkachuk
Gamaleya Scientific Research Institute of Epidemiology and Microbiology of the Health Ministry of the  
Russian Federation
109 - Genetically Engineered Tuberculosis Subunit Vaccine (15 min.)
 
13:00 - 14:00  Lunch
14:00 - 17:30  Advances in Vaccine Research (II)
Chairs: A.L.Ginzburg, Vice President of the Russian Academy of Medical Sciences, M.D., Professor, Director 
of Gamaleya Scientific Research Institute of Epidemiology and Microbiology of the Health Ministry of the 
Russian Federation, 
A.P.Kozlov, Doctor of Biological Sciences, Professor, Director of the Biomedical Centre (St.Petersburg, Russia)        
 
Antonio Lanzavecchia, MD
Director of the Institute for Research in Biomedicine (Switzerland)
110 - Keynote presentation: Broadly Neutralizing Antibodies for Serotherapy and Vaccine Design (30 min.)
Alexander Schmidt, MD
Director, Clinical Research and Translational Science, GlaxoSmithKline Biologicals (US)
111 - Update on Dengue Vaccines (20 min.)
Li Xiuling     
National Vaccine and Serum Institute (China)
112 - Development of Enterovirus 71 Vaccine (20 min.)
Shen Shuo, PhD     
Wuhan Institute of Biological Product (China)
113 - Epidemics of Acute Gastroenteritis Caused by Viruses and Vaccine Development in China (20 min.)
Luigi Buonaguro, MD    
Ist. Naz.Tumori “Fond. G. Pascale” (Italy)
114 - Virus-Like Particles and Particle Vaccines (20 min.)
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15:50 - 16:10  Break
Dan Barouch, MD, PhD
Director of the Centre for Virology and Vaccine Research in the Department of Medicine at Beth Israel Dea-
coness Medical Center (US)
115 - Novel HIV Vaccine Strategies (20 min.)
Jay A. Berzofsky, MD, PhD
Chief, Vaccine Branch, Center for Cancer Research, National Cancer Institute (US)
116 - Strategies and Mechanisms for Induction of Mucosal T Cell Immunity (20 min.)
HONORARY LECTURE:
José Esparza, MD, PhD
Senior Advisor on HIV Vaccines of the Bill and Melinda Gates Foundation (US)
117 - 30 Years of HIV Vaccine Research (40 min.)
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Speaker Schedule
Monday, September 9, 2013
Grand Conference-Hall    
9:30 - 12:00   Advances in Antiviral Drug Discovery (I) 
 
Chairs: A.I. Mazus, M.D., Professor, Head of the Moscow City Centre for AIDS Prevention and Treatment 
(Russia)   , 
Robert R. Redfield, M.D., Associate Director of the Institute of Human Virology, University of Maryland School 
of Medicine (US)       
 
PLENARY LECTURE: 
Jan Balzarini, MD, PhD
Laboratory of Virology and Chemotherapy, Rega Institute (Belgium)
118 - The Dense Glycan Shield on the HIV Envelope: the Achilles Heel of the Virus? (30 min.)
John G. Bartlett, MD
Director, HIV Care Program, The Johns Hopkins Hospital (US)
119 - The Anti-HIV Drug Pipeline (20 min.)
S.N.Kochetkov
Laboratory of Enzymology of Transcription, Engelhardt Institute of Molecular Biology, Russian Academy of 
Sciences
120 - Development of New HIV Inhibitors (20 min.)
Fujie Zhang, MD     
National Centre for AIDS/STD Control and Prevention (China)
121- Progress, Achievements and Challenges: a Review of China’s Free Antiretroviral Therapy Program 
(20 min.)
Anders Vahlne, MD    
Karolinska Institute (Sweden)
122 - Peptide Inhibitors of HIV (20 min.)
James Rooney, MD
Vice President of Medical Affairs, Gilead Sciences, Inc. (US)
123 - New Antiretroviral Therapies (20 min.)
Speaker Schedule
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Leonid Margolis, PhD     
Head, Section of Intercellular Interactions, Eunice Kennedy Shriver National Institute of Child Health and 
Human Development (US)
124 - HIV Transmission and Pathogenesis in ex vivo Tissues (20 min.)
12:00 - 13:00   Lunch
13:00 - 14:00   Official Opening Ceremony of the Conference
  Welcoming Remarks
14:00 - 14:45   Special Opening Lecture 
A.I. Mazus, M.D., PhD, Head, Moscow Center for HIV/AIDS Treatment and Prevention, 
welcoming Ram Petrov, MD, PhD, Head, Immunology Section, Institute of Bioorganic 
Chemistry, Russian Academy of Sciences who will introduce Robert C. Gallo, M.D., Director and 
Professor  Institute of Human Virology, University of Maryland School of Medicine, Member, 
United States National Academy of Sciences and Co-Founder of the Global Virus Network  
Robert C. Gallo, MD   
Institute of Human Virology, University of Maryland School of Medicine (US)
A personal journey with human retroviruses
14:45 - 15:00   Break
15:00 - 17:00  Advances in Antiviral Drug Discovery (II)
Chairs: C. David Pauza, Ph.D., Associate Director of the Institute of Human Virology, University of Maryland 
School of Medicine (US)   , 
Leonid Margolis, Doctor of Biological Sciences, Professor, Chief of the Section of Intercellular Interactions 
(National Institutes of Health)(US)  
Alain Lafeuillade, MD    
Progress toward a HIV cure 
125 - Department of Infectious Diseases, Toulon General Hospital (France) (20 min.)
Luis Menéndez-Arias, PhD    
Centro de Biología Molecular “Severo Ochoa” (CSIC-UAM) (Spain)
126 - Questions and challenges in HIV drug resistance: A molecular perspective (20 min.)
Speaker Schedule
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Vadim Bichko, MD 
Viriom Ltd. (Russia) 
127 - Safety, pharmokinetics and efficacy of VM-1500, a novel reverse transcriptase inhibitor, In 
healthy volunteers and HIV-infected patients (20 min.)
Ulrike Protzer, MD    
Institute of Virology TU Munich (Germany)
128 - Cure of HBV infection: can APOBEC3 deaminases mediate it? (20 min.)
A.I. Mazus, MD    
Director, Moscow Center for HIV/AIDS Treatment and Prevention (Russia)
Summary remarks (10 min.)
16:30 - 16:45  IHV Lifetime Achievement Award for Scientific Research to Vadim Agol, MD, PhD., DSc
  Introduction by Leonid Margolis, PhD
16:45 - 17:00   IHV Lifetime Achievement Award for Public Health to Jose Esparza, MD, PhD.
  Introduction by Robert C. Gallo, MD
17:00 - 17:45  Special Lecture Honoring the IHV Lifetime Achievement Award Winners
Konstantin Chumakov, PhD     
Chief of the Laboratory of Method Development, Division of Viral Products in the Food and Drug  
Administration (US)
129 - Polio Vaccines: The Past, Present and the Future 
17:45   Adjourn
19:30  IHV Gala Awards Banquet 
  Yar Restaurant
Speaker Schedule
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Speaker Schedule
Tuesday, September 10, 2013
Conference-Hall Sector B+C    
9:00 - 12:15   Mechanisms of Viral Pathogenesis 
 
Chairs: Peter Horal, Ph.D., University of Gothenburg (Sweden)     
B.S. Naroditsky, Ph.D.,Prof., Assistant Director, Gamaleya Scientific Research Institute of Epidemiology and 
Microbiology of the Health Ministry of the Russian Federation     
 
REINHARD KURTH HONORARY LECTURE – Introduction by Robert C. Gallo, MD   : 
William Hall, MD   
University College, Dublin (Ireland)
130 - HTLV-I and Adult T Cell Leukemia/Lymphoma (ATLL) : Cellular and Molecular Basis of 
Transformation (30 min.)
Stephan Becker, PhD   
Institute of Virology at the University of Marburg (Germany)
131 - Replication and Assembly of Filoviruses (20 min.)
Guido Poli, MD   
Head, AIDS Immunopathogenesis Unit, San Raffaele Scientific Institute (Italy)
132 - A Novel Pathway of Proviral HIV-1 Latency Regulated by Aminoacid Starvation and HDAC-4 (20 min.)
Erica Ollmann Saphire, PhD     
Department of Immunology and Microbial Science of the Scripps Research Institute (US)
133 - Ebola virus matrix: structural transformation begets multiple structures in the virus life cycle (20 min.)
Massimo Palmarini, DVM, PhD, FRSE    
Chair of Virology, University of Glasgow Centre for Virus Research (UK)
134 - Host Restriction of Schmallenberg Virus (20 min.)
10:50 - 11:00   Break
C. David Pauza, PhD   
Institute of Human Virology, University of Maryland School of Medicine (US)
135 - HIV-associated immunodeficiency despite potent antiretroviral therapy with CD4 T cell  
reconstitution (20 min.)
  Member, GVN15th Annual International Meeting of the Institute of Human Virology 26
INTERNATIONAL MEETING
1
5
T
H
 
A
N
N
U
A
L
Institute of Human Virology in partnership with 
the Global Virus Network and The Moscow 
Center for HIV/AIDS Prevention and Treatment
SEPTEMBER 8 –12, 2013  |  MOSCOW
CONTENTS SPEAKER SCHEDULE EVENTS SCHEDULE
1
5
T
H
 
A
N
N
U
A
L
ABSTRACTS INDEX
Speaker Schedule
Michael Bukrinsky, MD, PhD   
Department of Microbiology, Immunology and Tropical Medicine at the George Washington University (US)
136 - HIV-1 Nef regulates activity of endoplasmic reticulum chaperone calnexin (20 min.)
HONORARY LECTURE 
V.I.Agol, MD, PhD, DSc
M.P.Chumakov Institute of Poliomyelitis and Viral Encephalitis, Russian Academy of Medical Sciences (Russia)
137 - Interplay Between Host Defenses and Viral Anti-defenses: A Major Factor of Cytopathogenicity 
of Picornaviruses (35 min.)
12:15 - 13:30   Lunch
13:30 - 17:00   Mechanisms for Virus Transmission
Chairs: Salim Abdool Karim, M.D., Ph.D., President of South African Medical Research Council (South African 
Republic)   ,
Saulius Chaplinskas, M.D., Ph.D., Director, Center for Communicable Diseases and AIDS, Vilnus, Lithuania
PLENARY LECTURE: 
Diane Griffin MD, PhD          
Alfred and Jill Sommer Professor, Chair of the Department of Molecular Microbiology and Immunology, the 
Johns Hopkins Bloomberg School of Public Health (US)
138 - Understanding protective immunity: Lessons from measles (30 min.)
Barry J. Beaty, PhD    
University Distinguished Professor, Department of Microbiology, Immunology and Pathology, Colorado State 
University (US)
139 - Dengue Vector Control:  Critical Needs and Opportunities for Helping to Control the Dengue 
Pandemic (20 min.)
Myron Essex, DVM, PhD 
Mary Woodard Lasker Professor of Health Sciences Harvard School of Public Health, Harvard University (US)
140 - Reversing the Epidemic of HIV-1C in Southern Africa with Treatment as Prevention (20 min.)
Steven O’Brien
St. Petersburg State University (Russia)
141 - Gene Discovery and Data Sharing in Genome Wide Association Analyses: lessons from AIDS 
genetic restriction genes (20 min.)
15:00 - 15:10 Break
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E.A.Tkachenko, MD, PhD, DSc
M.P. Chumakov Institute of Poliomyelitis and Viral Encephalitis, Russian Academy of Medical Sciences (Russia)
142 - Sochi Virus as a Highly Pathogenic and Life-threatening Agent (20 min.)
 
Janusz T. Paweska, DVSc, dr hab, Prof Vet Sci   
Head, Centre for Emerging and Zoonotic Diseases, National Institute for Communicable Diseases National 
Health Laboratory Service (South African Republic)
143 - Rift Valley Fever Virus: a Virus with Potential for Global Emergence (20 min.)
E.I.Korenberg
Gamaleya Scientific Research Institute of Epidemiology and Microbiology of the Health Ministry of the Russian 
Federation
144 - Viral-Bacterial Mixed Infections Transmitted by Ticks: Diagnosis and Prevention in Russia (20 min.)
Guodong Liang, MD    
National Institute for Viral disease Control and Prevention, China CDC (China)
145 - Arbovirus and Related Infectious Diseases in China (20 min.)
Xiaoping Dong, PhD    
National Institute for Viral Disease Control and Prevention, China CDC (China)
146 - Understanding the Pathogenesis of Prion and Surveillance for Human Prion Diseases in China (20 min.)
Saulius Chaplinskas, MD, PhD
Director, Center for Communicable Diseases and AIDS (Lithuania)
147 - Globalization and New Challenges Caused of Communicable Diseases (20 min.)
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Wednesday, September 11, 2013
Conference-Hall Sector B+C    
9:00 - 12:00   Viruses and Cancer 
 
Chairs: Volker Erfle, Helmholtz Centre (Germany)   , 
A.D.Kaprin, M.D., Professor, Director of P.Herzen Moscow Research Oncology Institute of the Health Ministry 
of Russia     
 
OPENING COMMENT: 
Robert C. Gallo, MD   
Institute of Human Virology, University of Maryland School of Medicine (US) (10 min.)
Silvia Franceschi, MD
Special Advisor, Head, Infections and Cancer Epidemiology Group, International Agency for Research on 
Cancer (IARC) (France)
148 - HPV, HIV, and Cancer: A Global Challenge (20 min.)
Anna Linda Zignego, MD, PhD
Director, Interdepartmental Center MaSVE, Department of Experimental and Clinical Medicine, University 
of Florence (Italy)
149 - HCV and Lymphoma (20 min.)
Franco M. Buonaguro, MD      
Director, Molecular Biology and Viral Oncogenesis Unit, National Cancer Institute “Fondazione G. Pascale” (Italy)
150 - Carcinogenesis of HPV (20 min.)
Patrick Moore, MD, MPH     
Professor, Department of Microbiology and Molecular Genetics, School of Medicine and Department of 
Infectious Diseases and Microbiology, University of Pittsburgh (US)
151 - Tumorigenic Polyoma Viruses (20 min.)
10:20 - 10:40   Break
Luigi Chieco-Bianchi, MD   
Immunology and Molecular Oncology, Veneto Institute of Oncology, Dept of Surgery, Oncology &  
Gastroenterology, University of Padua (Italy)
152 - Insights into the pathogenesis of HHV8-driven body cavity lymphomas (20 min.)
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Masao Matsuoka, MD, PhD
Institute for Virus Research, Kyoto University (Japan)
153 - Molecular Pathogenesis by HTLV-1 bZIP Factor (20 min.)
William A. Blattner, MD
Professor and Associate Director, Institute of Human Virology, University of Maryland School of Medicine (US)
154 - HIV and Cancer in Africa (20 min.)
A.P.Kozlov
Professor and Director, Biomedical Center (Russia)
155 - Evolution by Tumor Neofunctionalization and Phenomenon of Tumor Specifically Expressed, 
Evolutionarily Novel (TSEEN) Genes (20 min.)
14:00 - 18:00   Clinical Management of Co-Morbidities in HIV/AIDS 
 
Chairs: John G. Bartlett, M.D., Director of the HIV Care Program, the Johns Hopkins Hospital (US), A.I.Mazus, 
M.D., Professor, Head of the Moscow City Centre for HIV/AIDS Prevention and Control (Russia)   , 
Robert R. Redfield, M.D., Assistant Director of the Institute of Human Virology, University of Maryland School 
of Medicine (US)       
 
Barry Peters, MB BS, DFFP, MD, FRCP
King’s College London (UK)
156 - HIV and metabolic disease: Clues to control of HIV infection from the immune and virological 
response to high dose Vitamin D challenge (25 min.)
Riccardo Dolcetti, MD
Head, Cancer Bio-Immunotherapy Unit, IRCCS – National Cancer Institute (Italy)
157 - Pathogenesis of Epstein-Barr Virus-driven Lymphomas of HIV+ Patients: new insights of  
potential clinical relevance (25 min.)
Shyam Kottilil, MD, PhD
National Institute of Allergy and Infectious Diseases (US)
158 - Hepatitis C Treatment Update: Current Status and Future Directions (25 min.)
Rohit Talwani, MD   
Institute of Human Virology, University of Maryland School of Medicine (US)
159 - Hepatitis B Treatment Update: Current Status and Future Directions (25 min.)
15:40 - 15:55   Break
Bruce Gilliam, MD   
Institute of Human Virology, University of Maryland School of Medicine (US)
160 - Treatment Strategies to Minimize the Impact of Antiretroviral Drug Toxicities (25 min.)
Speaker Schedule
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E.M.Bogorodskaya, MD, PhD
Moscow City Research and Practical Centre for Tuberculosis Control (Russia)
161 - Anti-tuberculosis Treatment for HIV-positive Patients in Moscow (20 min.)
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101
Biomedical Prevention of HIV/AIDS in Russia
E.V. Karamov and R.M. Khaitov
Research Institute of Immunology, Federal Medical 
and Biological Agency,RU
The epidemic of HIV/AIDS in Russia is currently in its 
concentrated phase characterized by concomitant 
coinfections (hepatitides B and C and tuberculosis). 
Although subtype A1 is dominant, subtype B and 
CRF 03 (A/B recombinant) are also present. Recent 
subepidemic eruptions of HIV infection in Siberia/Urals 
and the Far East have involved A/G recombinant and 
subtype C, respectively. Approaches to biomedical 
prevention of HIV/AIDS in Russia include vaccine and 
microbicide development. 
Candidate HIV vaccines have been developed 
independently by three Russian research centers. In 
one of them, the conjugated protein–polymer vaccine 
VICHREPOL, use is made of an original domestic 
immunoadjuvant polyoxydonium. This candidate, 
developed in the Institute of Immunology, is currently 
undergoing a phase II clinical trial.
A broad-coverage screening of natural and synthetic 
compounds for anti-HIV activity is currently underway 
in Russia, aiming at identification of chemicals 
appropriate for pre-exposure prophylaxis and use 
as microbicides. Unique compositions of antivirals 
have been developed, as well as nanotechnology-
based means of their delivery, the combinations 
thereof showing significant promise as microbicide 
preparations. 
The presentation will highlight the present state of 
research on biomedical prevention of HIV/AIDS in 
Russia.
102
HIV/AIDS vaccines in Russia: clinical trials 
and estimation of acceptance in population
1Gudima G., 1Sidorovich I., 1Karamov E., 
2Bogachanskaya N., 2Pavlov S., 2Efimenko S., 
2Reshetnikov A., 1Khaitov R.
1Institute of Immunology FMBA, Moscow; 2Institute 
of Sociology of Medicine, 1st Moscow Medical 
University, RU
HIV/AIDS vaccines and also PrEP are considered as 
the most perspective approaches to control HIV/AIDS 
epidemic. Candidate conjugated polymer-subunit HIV 
vaccine VICHREPOL, developed in Moscow Institute 
of Immunology, successfully passed phase I clinical 
trials and now is at the start of phase II trials. Two 
other candidate vaccines (DNA-based and viral vector-
based) are also passed phase I trials. Positive effect of 
vaccination depends of the coverage of population and 
this coverage depends of vaccine uptake. Estimation 
of possible uptake of HIV vaccine is very important 
to provide its further effective application. Pilot 
investigation of readiness for HIV vaccination in Russia 
(Moscow region) was performed (416 persons, 254 
(61%) – men, 162 (39%) – women, age of 16-55). 
60% of respondents were ready for HIV vaccination. 
79% of respondents with risk of HIV infection, agreed 
to be vaccinated vs 48% of those disclaimed the risk 
of  HIV infection. Readiness for HIV vaccination is 20% 
lower in respondents with children vs childless. In 
case of 30% vaccine efficacy readiness for vaccination 
was 3.5 points of 10; in case of 50% efficacy – 5.2 
points of 10; 8.8 points of 10 – in case of 90-95% 
efficacy. Readiness for vaccination also depends from its 
duration, number of doses in course, possible adverse 
side effects, mode of vaccination. 20% of respondents 
agreed only for free vaccination, 45% – for paid 
vaccination. Readiness for HIV vaccination is lower in 
general population (60% vs 78%) and in HIV infection 
risk groups (79% vs 95-97%) in Russia vs some other 
countries [Suraratdecha et al., 2005]. It is necessary to 
improve education programs aimed to inform on HIV 
vaccines development, its safety and application.15th Annual International Meeting of the Institute of Human Virology 40
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Genetic factors defining resistance and 
susceptibility to HIV/AIDS
Kofiadi IA, Alexeev LP, Khaitov RM
FSBI “NRC Institute of Immunology” FMBA of 
Russia, RU
One of the priorities for fundamental biomedical 
science is the discovery of the molecular-genetic 
basis of HIV pathogenesis. The progress in this area 
widens the possibilities for further improvement of 
HIV/AIDS prevention and therapy approaches. In this 
framework we have studied the population distribution 
of CCR5 rs333, CCR2 rs1799864, SDF1 rs1801157, 
HCP5 rs2395029, HLA-C rs9264942 and HLA-B*5701 
genetic polymorphisms associated with susceptibility 
to HIV and AIDS and antiviral drugs intolerance 
among 1120 seronegative individuals comprising 12 
ethnically distinct groups inhabiting Russia, Belarus, 
Ukraine, Kazakhstan, Kyrgyzstan and Moldova(Pomors, 
Russians(Vologda and Pskov region), Belarus, 
Ukrainians, Gagauz, Udmurts, Tatars, Chechens, 
Kazakhs, Kyrgyz, Tuvinians). The rs333 variant is 
represented at most in the population of Pomors. The 
homozygotes who have significantly lower risk of HIV 
infection comprising 3% of the population. The least 
frequency of CCR5 polymorphism was described for 
Chechens, Kazakhs, Kyrgyz, Tuvinians: 6, 6, 5 and 
2% correspondingly. The highest incidence of CCR2 
polymorphism was described for Chechens, Kazakhs 
and Kyrgyz. The other alleles under study did not reveal 
significant differences in distribution. The protective 
effect of the studied polymorphisms in CCR5, CCR2, и 
SDF1 genes is characterized as cumulative. Based on the 
frequencies of three-loci genotypes we have established 
the values of relative hazard of AIDS onset and relative 
hazard of AIDS-caused death for the populations under 
study. The risks fall in range 0.79-0.94 and 0.76-0.93, 
correspondingly. We have found that interpopulation 
genetic variability confers for statistically relevant 
differences in the hazards estimated.
104
Cell-to-cell transmission of HIV: role of 
virological synapse
Mazurov DV, Filatov AV
Institute of Immunology, RU
HIV-1 infects CD4+ T-lymphocyte by cell free viral 
particles released from the surface of effector cells or 
after the formation of intercellular contact between 
infected cell and healthy lymphocyte. The last 
way of infection was designated as cell-to-cell viral 
transmission. The current studies suggest that cell-to-
cell transmission of HIV occurs in peripheral lymph 
nodes at the early stage of infection and is more 
efficient pathway of virus dissemination than cell-free 
infection. One of the most accepted models of HIV 
transmission is the formation of virological synapse 
(VS); tight intercellular adhesion junction sharing 
structural similarity with immunological synapse. VS 
forms after HIV surface protein gp120 expressed on 
the plasma membrane of infected cells in prefusogenic 
conformation recognizes CD4 receptor on target cell. 
Viruses transmitted across VS undergo endocytosis 
by target cells, so that viral entry occurs via endocytic 
compartments and not via cell surface. This feature 
of cell-to-cell transmission accounts for the resistance 
of HIV to the neutralizing antibodies. Although the 
different stages of HIV cell-to-cell transmission have 
been extensively studied, the levels of correlation 
between virus transmission and targets infection were 
not accurately quantified. To fill up the gap in our 
understanding of cell-mediated viral infection, we have 
developed a new methods and improved vectors to 
quantify the levels of VS formation, cell-to-cell infection, 
and macromolecular transport across the cell-cell 
contact. New T cell lines stably producing recombinant 
virus like particles and reporter RNA, as well as modified 
target cells were generated.
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Rationale for HIV vaccines design
Irina A.Nikolaeva, Igor G.Sidorovich
National Research Center – The Institute of 
Immunology of the Federal Medical- Biological 
Agency, RU
Development of an effective and safe HIV vaccine 
presents unique challenges. Despite the progress in 
understanding the biology of HIV-1 and its recognition 
by the human immune system, we have not yet 
developed an efficacious HIV-1 vaccine. During the 
last years, the results were obtained that has given 
hope that vaccination may prevent HIV-1 acquisition. 
The results of post-RV144 correlates and sieve analyses 
suggest that vaccine worked probably involving an 
immunological mechanism in the second variable 
loop (V2). A high resolution structure of the envelope 
trimer was solved, and  this information is being used 
for the design of new generations of vaccines aimed 
at inducing protective antibodies. New techniques 
have facilitated the discovery of new human broadly 
neutralizing antibodies (BrNAbs) that target and 
delineate diverse conserved epitopes on the envelope 
glycoprotein spike. The epitopes of these BrNAbs 
can serve as templates for immunogen design aimed 
to induce similar antibodies. A separate goal of HIV 
vaccine research is to identify the best strategy for 
immunization and delivery agents. Several vectors 
and adjuvants have been developed. Significant 
advances have been made towards the development 
of tools to assess preclinical efficacy and understanding 
the correlates of protection in non human primate 
models. We observe the preventive potential of 
microbicides, PrEP, and earlier antiretroviral treatment 
of infected individuals has been demonstrated. All of 
these interventions may have a significant impact in 
reducing the incidence of HIV infections. However a 
safe and efficacious vaccine will be the most efficient 
way to control global HIV-1 pandemic, and scientific 
opportunities look promising.
106
Enhance expression of transgene in 
adenovirus
Ataullakhanova, RU
No abstract provided.
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The modern methods for HIV/AIDS vaccine 
evaluation
S.V. Korobova,  I.G. Sidorovich, G.V. Kornilaeva
FSBI “NSC Institute of Immunology” FMBA of RU
The spread of HIV/AIDS increases worldwide, a safe 
and efficacious vaccine remains the cornerstone 
for a prevention strategy to stop HIV-1 epidemic. 
Both humoral (neutralizing antibodies) and cellular 
(CTL) responses are able to control HIV infection. 
Non-neutralizing HIV-specific antibodies could play 
an important role in preventing or controlling HIV 
infection. These antibodies can bind to infected cells 
and recruit innate immune effector cells, such as natural 
killer (NK) cells, to lyse infected cells through antibody-
dependent cellular cytotoxicity (ADCC) and antibody-
dependent cell-mediated virus inhibition (ADCVI). 
The measurement of immune responses directed 
specifically against the HIV is critical for understanding 
the interplay between the virus and the host immune 
system. By characterizing the immunological correlates 
of protection against HIV infection, such measurements 
will aid in the development of efficacious prophylactic 
vaccine. To improve vaccine antigens and adjuvant, it is 
also necessary to asses a similarity of vaccine – and virus 
– induced immune responses The evaluation of antigen-
specific humoral response includes measurement 
amount and specificity of vaccine-induced antibodies 
(in ELISA or WB), their neutralizing activity and ADCC or 
ADCVI. ELISPOT, intracellular cytokine flow cytometry 
assays and Luminex are the most common assays to 
determine CTL response. They all determine immune 
response by the detection of the cytokines   (IFN-
gamma, TNF-alpha, IL2) secreted by cells upon antigen-
stimulation. MHC tetramer binding assay measures the 
absolute number of cells that recognize a particular 
epitope without providing any information regarding 
the functionality of the cells.
108
Development of universal vaccines against 
flu: reality and prospects
Shmarov M.M.
Gamaleya Research Institute of Epidemiology and 
Microbiology, RU
Two surface glycoproteins hemagglutinin 
and neuraminidase are the main antigens for 
obtaining traditional flu vaccines due to their high 
immunogenicity and ability to induce generation of 
neutralizing antibodies. High genetically instability of 
influenza virus provides  antigenic diversity of these 
glycoproteins between strains. Subunit vaccines based 
on one of these surface antigens are characterized by 
narrow specificity. Modern vaccines should provide 
protection against several or all subtypes of influenza A 
viruses. In addition sporadic influenza outbreaks  
of newly emerged influenza A viruses may cause the 
next pandemic.
 
Today there are no flu vaccines of a wide range of 
action, so-called “universal” vaccines. Several flu 
vaccines with a broad cross-protectivity are tested in 
different phases of clinical trials.
 
In this report the analysis of the modern researches 
directed on creation of flu “universal” vaccines 
including data obtained by researchers of Gamaleya 
institute of epidemiology and microbiology is  
carried out.
Genetic immunization technology is used for 
development of “universal” vaccine. Recombinant 
pseudoadenoviral particles coding of influenza virus 
conservative antigens were used as a vector for gene 
delivery. Polypeptide, containing hemagglutinin 
conservative epitopes, was used in addition to 
traditional influenza conservative antigens M1, M2 and 
NP. Animal experiments demonstrated that developed 
vaccines were very efficient against different influenza 
subtypes (80%-100% survivability).
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Problems and prospects of development of 
the subunit TB vaccine  
Tkachuk A.B., Lunin V.G., Karyagina A.S., Gintsburg 
A.L. Gamaleya Research Institute for Epidemiology 
and Microbiology, RU
Tuberculosis (TB) causes about 1.4 million deaths each 
year. Currently the only licensed anti-tuberculosis vaccine 
is Bacille Calmette-Guérin (BCG). This live attenuated 
vaccine has been in use for over 80 years and has 
displayed up to 80% efficacy against serious forms of the 
disease, e.g., meningitis, in children. However, efficacy in 
adults against pulmonary tuberculosis ranges from 0 to 
80% in different trials. The protective immunity generated 
by BCG decreases with time, and almost disappears 
after 20-25 years, resulting in a vulnerability of the adult 
population to primary infection and reactivation of latent 
TB. Thus, development of an effective preventive vaccine 
and new “post-infection” vaccine are still important aims 
of vaccinology.
In this study we report the development of novel 
subunit protein-based vaccine against tuberculosis. Our 
vaccine consists of two recombinant mycobacterium 
proteins - Ag85A and fusion protein ESAT6-CFP10. These 
antigens are strongly recognized by T cells and they 
have demonstrated protective efficacy in animal models. 
However, because the protein component of the subunit 
vaccine is poorly immunogenic, the recombinant protein 
vaccine was adjuvanted with novel, three-component 
adjuvant system composed of the dextran, cationic DEAE-
dextran and oligodeoxynucleotide CpG. This adjuvant 
was chosen on the basis of its ability to induce strong 
protective immunity in animal models of M. tuberculosis 
infection, by delivering a TLR9 ligand into the endosomal 
pathway. Recombinant vaccine proteins possess dextran-
binding domain, which helps create «depot» effect and 
provide prolonged interaction of vaccine antigen  
with T-cells.
We investigated immunogenicity and protection 
properties of our vaccine on mice and guinea pigs models 
of tuberculosis, and also performed toxicity studies. We 
demonstrated that our subunit vaccine stimulates th1 
immune response and is protective against tuberculosis 
with the same efficacy as BCG. Furthermore, our vaccine 
showed good result in toxicity studies in mice, guinea pigs 
and rabbits.
110
Broadly neutralizing antibodies for 
serotherapy and vaccine design
Antonio Lanzavecchia
Institute for Research in Biomedicine, Bellinzona and 
Institute of Microbiology, DE
Memory B lymphocytes and long-lived plasma cells 
represent a repository of the antigenic experience of 
an individual. By analyzing the specificity and function 
of these cells we can gain insights into the human 
immune response to pathogens and vaccines, identify 
correlates of protection, and isolate neutralizing 
antibodies and protective T cells. To interrogate 
human memory B cell and plasma cell repertoires we 
developed two culture-based high-throughput methods 
that are used to isolate, with high efficiency, human 
monoclonal antibodies of distinctive specificities. 
Unusually potent neutralizing antibodies against human 
cytomegalovirus were isolated from infected donors 
and used to identify the viral ligands and to design 
an experimental vaccine. We also isolated antibodies 
of exceptional breadth, such as a pan-influenza A 
neutralizing antibody and an antibody that neutralizes 
both respiratory syncytial virus and metapneumovirus. 
By targeting conserved structures, these broadly 
neutralizing antibodies are less prone to select escape 
mutants and are therefore promising candidates for 
prophylaxis and therapy of infections as well as tools for 
the design of improved subunit vaccines. 
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Update on dengue vaccines
Alexander C. Schmidt
GlaxoSmithKline Biologicals, US
Forty percent of the world’s population is at risk for 
dengue, and 100 million apparent infections are 
estimated to occur annually. In a minority of cases, 
dengue fever progresses to severe disease at the time 
of defervescence, inducing a capillary leak syndrome 
accompanied by thrombocytopenia that can result 
in shock and organ failure. Thus the medical need for 
a dengue vaccine is obvious. The four dengue virus 
serotypes are transmitted by Aedes mosquitoes, and 
protective immunity against the infecting serotype 
(homotypic immunity) is long lived and thought to 
be conferred by virus-neutralizing antibodies and 
some T cell help. However, antibodies induced by one 
serotype often cross-react with the other serotypes. 
If antibodies fail to neutralize and instead opsonize, 
they can enable the virus to infect IgG receptor-
bearing cells. This phenomenon, termed antibody-
dependent enhancement, is thought to play a role in 
the pathogenesis of severe dengue, and is of concern 
to vaccine developers. Several investigational dengue 
vaccines are currently in clinical development, and 
many different vaccination approaches are being 
explored. These span from live-attenuated dengue 
viruses to chimera between yellow fever and dengue 
viruses, to subunit, DNA, and whole virus inactivated 
vaccines. A recent Phase 2b study of the vaccine most 
advanced in development did not show statistically 
significant protection against disease due to any 
serotype, adding much uncertainty to the entire field. 
Our understanding of the contributions of humoral 
and cell mediated responses to protection and to 
pathogenesis is clearly less than perfect, and selection, 
presentation and adjuvantation of antigens need 
thought and attention.
112
The Development of Enterovirus 71 Vaccine
Li Xiuling, Zhang Zhongyang, Wang Xiaoxiao, Hao 
Chunsheng, Li Yi, Zhang Chong, Zhang Chen, Chen 
Ming, Ning haijing, Liu Yu, Chen Lei, Ma Shuhua,
Yang Yongjuan, Song Dongmei, Shen Xinliang
National Vaccine & Serum Institute, CN
Enterovirus 71 (EV71) is a major cause of epidemic 
outbreaks of hand-foot-and-mouth disease (HFMD) 
worldwide. The virus belongs to the family Picornaviridae, 
genus Enterovirus. 3 genotypes—A, B, and Cиand more 
than 10 sub-genotypes have been identified. After the 
initial identification of this virus in 1969, some large 
outbreaks of HFMD have been reported worldwide. 
EV71-induced HFMD is usually characterized by the 
formation of maculopapular or vesicular lesions on the 
skin and oral mucosa, especially on the palms, soles, 
and mouth.. There were a greater number of fatal cases 
with brainstem encephalitis, pulmonary edema and/or 
hemorrhage, and cardiopulmonary collapse. 
Developing effective vaccines is considered a top choice 
among all control measures. We evaluated the ability of 
inactivated virus vaccine to elicit neutralizing antibody 
and to provide protection against lethal infection of 
EV71 in suckling mice. The purity of EV71 vaccine was 
up to 96.8% by HPLC identification. The purified EV71 
vaccine induced high levels of neutralizing antibodies, 
these antibodies were shown to be protective against 
lethal infection when passively transferred to susceptible 
newborn mice. With a challenge dose of 50LD50 virus/
mouse, suckling mice born to dams immunized with 
inactivated virus showed 100% survival. In preliminary 
animal trial, no side effects were detected when monkeys 
were immunized with purified EV71 vaccine either at 
normal or large doses.
The vaccine was approved of the clinical evaluation in 
2009. The phase 1/2/3 clinical trail was completed in 
March, 2013. The data suggested that the inactivated 
EV71 vaccine had a clinically acceptable safety profile and 
good immunogenicity in healthy children and infants.
Our data indicated that inactivated EV71 vaccine is the 
choice of vaccine preparation capable of fulfilling the 
demand for effective control.  
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Epidemics of Acute Gastroenteritis Caused 
by Viruses and Vaccine Development in 
China
Shen Shuo
Wuhan Institute of Biological Product, China 
National Biotec Group (CNBG), CN
The leading etiological agents of viral gastroenteritis are 
group A rotaviruses, noroviruses, adenoviruses (type 40, 
41) and astroviruses in China in the last 20 years. The 
prevailing serotypes of rotaviruses are G type 1, 2, 3, 4 
and 9, while G8 has been emerged recently in China. 
Accordingly, trivalent and hexavalent vaccines are 
under development by the two Institutes under CNBG. 
The trivalent oral vaccines are reassortants of VP4 and 
VP7 genes of human strains and other backbone genes 
of Lanzhou lamb rotavirus (LLR). The safety of lamb 
rotavirus vaccine strain has been proved since licensing 
in 2000 in China. The phase 3 clinical trials of the 
trivalent vaccines are in the progress in Henan province, 
China. The hexavalent oral vaccines are reassortants of 
VP7 genes of human strains and the other genes of UK 
strain, developed by and collaborated with NIH, USA, 
and PATH. The preclinical studies at Wuhan Institute 
of Biological Product have been completed and the 
hexavalent vaccine is ready for phase 1 clinical study. 
The novoviruses are increasingly detected in epidemics 
of acute viral gastroenteritis and spontaneous cases 
of people of all ages in China, including the rapid 
spreading of the newly emerged pandemic GII.4 variant 
(Sydney strain 2012) to China. The new Sydney strains 
were isolated in different areas and analysis of complete 
sequence demonstrated the rapid evolution. The 
surveillances and epidemic studies of these emerging 
viruses support the development of vaccines against 
the infections caused by noroviruses. The new variant 
co-circulated with other genotypes of GI and GII 
genogroups in human and multiple valent vaccines 
may needed to be developed..
114
VLPs and particle vaccines
Luigi Buonaguro, MD
Ist. Naz.Tumori “Fond. G. Pascale,” IT
VLPs represent a powerful tool for vaccine 
development, representing the closest strategy 
to the native viruses for displaying and delivering 
conformational epitopes, with improved induction 
of antibodies and immune response in its whole. 
Moreover, the lack of genetic material makes VLPs 
the “safer counterpart” of live attenuated or killed 
viral vaccines which, indeed, may induce limited but 
possible undesired effects. 
VLP-based vaccines have been developed from both 
enveloped and non-enveloped viruses to target 
infectious and non-infectious diseases and are in various 
stages of development spanning preclinical evaluation 
to market. In particular, the only two preventive cancer 
vaccines licensed are based on VLP approach (HBV and 
HPV vaccines).
Overall, pre-clinical and clinical trials with different 
VLP-based vaccines have shown they are well 
tolerated and can be administered by a number of 
routes, including intramuscular, subcutaneous, oral or 
intranasal. VLP vaccines have also been demonstrated 
to be highly immunogenic and capable of stimulating 
protective immunity in a number of instances when 
administered with or without adjuvants. Their potent 
immunogenicity is a result of several factors, including 
the ability to incorporate key immunogenic properties 
of viruses into a single entity and to hit the cells relevant 
for initiate an effective adaptive immune response.
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Immune Correlates of Protection in Rhesus 
Monkeys
Dan Barouch
Beth Israel Deaconess Medical Center, Boston, 
MA,US
We have previously reported the protective efficacy 
of Ad26/MVA vector regimens expressing SIVsmE543 
Env/Gag/Pol antigens against SIVmac251 challenge.  
Here we assess the potential utility of adding a protein 
trimer boost to adenovirus based vaccine regimens.  
We produced stable SIV and HIV Env gp140 trimers 
and assessed the immunogenicity and protective 
efficacy of Ad prime, Env gp140 trimer boost regimens 
against SIVmac251 and SHIV-SF162P3 challenges in 
rhesus monkeys.  Vector prime, protein boost vaccine 
regimens induced higher titer binding and neutralizing 
antibodies compared with protein only regimens.  
Clinical studies to evaluate Ad26/MVA and Ad26/
protein vaccine regimens are planned.  
116
Strategies and mechanisms for vaccine 
induction of mucosal T cell immunity
Jay A. Berzofsky
Vaccine Branch, Center for Cancer Research, 
National Cancer Institute, NIH, US
Most HIV transmission is through mucosal surfaces.   
We previously found in mice that CD8 T cells must be in 
the local mucosa to prevent mucosal viral transmission.  
Intrarectal delivery was most effective, but not so 
practical.  We devised a strategy to mimic intrarectal 
delivery through the oral route by encapsulating 
antigens in nanoparticles enclosed in microparticles 
that protected against stomach acid and enzymes 
and released the nanoparticles in the large intestine 
for update by dendritic cells.  Different formulations 
resulted in selective release in the small or large 
intestine and T cell immunity in those sites, revealing a 
heretofore unknown subcompartmentalization between 
the small and large intestinal mucosal immune system.  
Delivery to the colon mimicked intrarectal delivery 
for protection of mice against intrarectal vaccinia 
virus challenge.  We translated this to macaques, 
showing similar selective delivery and some preliminary 
evidence of efficacy in a SHIV intrarectal challenge 
model.  The subcompartmentalization also implies 
that the homing receptors for T cells to traffic to the 
small and large intestine must differ.  We found that 
indeed, small intestinal DCs induce T cells to home 
to the small intestine, whereas colonic DCs induce 
homing to the colon.  This difference appears to 
correlate with different levels of retinoic acid production 
and differential induction of homing integrins and 
chemokine receptors.  Besides the ability to mimic 
the benchmark intrarectal immunization by a more 
acceptable route, such subcompartmentalization may 
be useful for selective immunization, and understanding 
the mechanisms involved in homing may allow 
selective targeting of T cells to the right compartment.
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30 Years of HIV Vaccine Research
José Esparza
Bill and Melinda Gates Foundation, Seattle, WA, US
Soon after HIV was discovered as the cause of AIDS in 
1983–1984, there was an expectation that a preventive 
vaccine would be rapidly developed. The first HIV 
vaccine vaccine paradigm was aimed at inducing 
neutralizing antibodies, with numerous recombinant 
envelope proteins tested in clinic al trials. It came to an 
end in 2003, with the negative results from the VaxGen 
trials in North America and Thailand.
The second paradigm aimed at inducing CD8+ T-cell 
responses, and it led to the development of DNA 
vaccines and of live-recombinant viral vectors, especially 
poxviruses and adenoviruses (Ad). The concept was 
tested in the STEP and Phambili trials, using an Ad5 
vector. The trials were stopped in 2007, after an 
interim review of STEP showed that the vaccine failed 
to prevent HIV infection or to decrease virus load in 
vaccinated volunteers who became infected, and 
even enhanced HIV acquisition in a subpopulation of 
vaccinated individuals. 
The current wave of vaccine development is attempting 
to induce more complex immune responses and 
exploring novel approaches.  The RV 144 trial in 
Thailand, which assessed the protective efficacy of 
a prime-boost protocol using a canarypox vectors 
followed by gp120 boosts, showed 31.2% efficacy in 
preventing HIV acquisition and presumptive immune 
correlates have been identified. The field is now 
exploring new leads that include the rational design 
of novel immunogens based on epitopes recognized 
by broadly neutralizing antibodies, live replication-
competent vectors and the role of potentially protective 
non-neutralizing antibodies. 
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118
The dense glycan shield on the HIV 
envelope: the Achilles heel of the virus?
Jan Balzarini
Rega Institute for Medical Research, BE
The envelope gp120 of HIV contains an unusual high 
amount of N-glycans that serves as a dense shield 
to hide immunogenic epitopes on gp120 against 
the immune system. There exists a wide variety of 
glycan-binding agents with different specificities to 
recognize carbohydrate moieties present on the HIV 
envelope. Several of the carbohydrate-binding agents 
(CBA) are potent inhibitors of at least four different 
pathways of HIV to infect virus-susceptible cells 
and to be transmitted to virus-exposed individuals. 
These CBAs have been demonstrated (i) to inhibit 
cell-free virus infection of CD4+ T-lymphocytes and 
macrophages, (ii) to block syncytia formation between 
persistently HIV-infected (gp120-expressing) cells and 
uninfected cells, (iii) to prevent virus capture by DC-
SIGN-expressing cells and (iv) to block transmission 
of DC-SIGN-captured virus particles to uninfected 
CD4+ T-lymphocytes. CBAs represent the only agents 
reported to be able to concomitantly interact with 
these four processes, which can be advantageous from 
a microbicide perspective. Interestingly, CBA drug 
pressure in cell culture forces the virus to select for 
mutant variants that have multiple N-glycan deletions 
in their envelope, and thus, to uncover immunogenic 
epitopes on gp120. Accumulation of such envelope 
mutations compromises the infectivity of the virus. 
Several gp120 antibodies show a markedly increased 
activity against such mutant viruses. CBAs may, 
therefore, represent an entirely novel therapeutic 
concept in that they inhibit virus entry into its 
susceptible cells, and prevent DC-SIGN-directed virus 
transmission, but in addition, they may trigger the host 
immune system as soon as drug-related (N-glycan) 
mutations appear in the viral envelope.
119
The Anti-HIV Drug Pipeline
John G. Bartlett
Johns Hopkins University School of Medicine, US
New Drugs by Class
NRTI:  Tenofovir alafenamide fumarate (TAF) is the 
pro-drug of tenofovir with advantages of slight increase 
activity and reduced renal/bone toxicity. The phase 2 
trial (Zolopa A. 2012 CROI, Abstr 99LB) compared TAF 
vs. another TDF prodrug (TFV, each with EFV, COBI/
FTC in 170 treatment naïve patients. At 24 weeks both 
groups achieved VL <50 c/mL; TAF showed better renal 
and bone safety.
InSTI: Dolutgravir (DTG) – New once daily DTG/2NRTIs 
that shows potency with good activity vs. RAL-resistant 
strains.
•		S/GSK	1265-744	(“744”):	This	is	a	next	generation	
InSTI with a T1/2 of 21-50d! 
NNRTI:  MK1439 – This new potent NNRTI showed 
exceptional potency with 25 mg monotherapy once 
daily (Anderson M, 2013 CROI;Abstr. 100).
•		RPV-LA:	A	novel	nanosuspension	of	RPV	with	steady	
state release after 600 mg given SC or IM every 3 
months.                 
Entry Inhibitors:  Cenicriviroc (CVC) antagonizes CCR5 
receptor, but also CCR-2 receptors to possibly reduce 
immune activation. ART activity is comparable to EFV.
•		BMS	663068	(or	BMS	068):	This	is	a	prodrug	of	BMS-
529 that binds gp125 to prevent HIV binding to CD4 
cells. A small trial showed 42 of 48 treatment-naïve 
patients responded; the 6 exceptions had a genetic 
factor that accounted for nonresponse.
Pharmacoenhancer: Cobicistat (COBI) is a potential 
substitute for RTV to boost ARVs and is already FDA-
approved in combination as EVG/COBI/TDF/FTC.
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Development of New HIV Inhibitors
S.N.Kochetkov
Laboratory of Enzymology of Transcription, 
Engelhardt Institute of Molecular Biology, Russian 
Academy of Sciences, RU
No abstract provided.
121
Progress, achievements and challenges: a 
review of China’s free antiretroviral therapy 
program
Fujie Zhang
National Center for AIDS/STD Control and 
Prevention, CN
In order to respond to the rapid emergence of a large 
number of AIDS cases and subsequent peak of death 
in the early 2000’s, Chinese government launched its 
National Free ART Program in 2002. The initial stage 
of this program mainly focused on former plasma 
donors at six provinces in central China under the 
China Comprehensive AIDS Response Program.  Since 
the release of “Four Free and One Care” policy in late 
2003, the ART program was quickly scaled up to the 
whole country and had covered 64% of individuals 
knows to have AIDS by the end of 2006. As more 
resources became available, second line drugs, free 
viral load and free resistance tests became parts of 
routine services successively between 2007 and 2010, 
which represented the standardization of China’s 
ART program.  Due to the encouraging findings of 
ART’s both survival and prevention benefits, China’s 
ART program stepped into a phase of fast expanding. 
The sum of newly treated patients in 2011 and 2012 
almost equal the accumulative sum of the previous 
nine years. By the end of 2015, this program aims to 
treat 358,600 HIV/AIDS patients in China. With the fast 
expansion of the program, China successfully decreased 
the overall mortality of HIV from 39.3 per 100 person-
years in 2002 to 14.2 per 100 person-years in 2009. 
Progress indicators also suggested improvement at 
implementation. However, there are many challenges 
remain, which in long run may threaten the 
sustainability and effectiveness of the program. More 
attention should be paid to the groundwork of the 
program and more efforts should be made to improve 
the overall capacity of the program and its related 
systems.
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122
Peptide Inhibitors of HIV
Anders Vahlne, MD
Karolinska Institute, SE
No abstract provided.
123
New HIV Therapies
James F Rooney, Michael Miller, Andrew Cheng
Gilead Sciences, US
The advent of triple drug highly active antiretroviral 
therapy in 1996 was a turning point in the battle to 
control HIV disease. For the first time, HIV replication 
could be effectively limited resulting in marked 
improvements in morbidity and mortality from HIV 
infection. However, the treatment regimens were 
complex with patients having to take many pills at 
different times during the day, and the regimens were 
associated with significant long term side effects. 
Subsequent treatment strategies have focused on 
simplification of dosing to facilitate adherence and 
better tolerated regimens. Various combination pills 
were developed beginning with Combivir ( zidovudine/
lamivudine) given twice daily and then Truvada 
(tenofovir DF/emtricitabine) given once daily in 
combination with a third or fourth drug. This led to the 
development of single tablet regimens (STR), a single 
pill that provided complete therapy for treatment of 
HIV infection. The first STR was Trizivir (zidovudine/
lamivudine/abacavir) given twice daily, which was 
followed by the once daily STRs Atripla ( tenofovir 
DF/emtricitabine/efavirenz), Complera (tenofovir 
DF/emtricitabine/rilpivirine), and Stribild (tenofovir 
DF, emtricitabine, cobicistat, elvitegravir), which are 
now the most commonly used medications for the 
initial treatment of HIV infection. New drugs are in 
development, including the tenofovir prodrug TAF 
(tenofovir alafenamide fumarate) and the integrase 
inhibitor dolutegravir, which may offer advantages in 
safety, efficacy, and simplicity of dosing, and could be 
included in future STRs. 
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Male-to-Female HIV-1 Transmission: Lessons 
from Ex Vivo
Leonid Margolis
National Institute of Child Health and Human 
Development, NIH, US
The mechanisms of male-to-female HIV-1 transmission 
mediated by semen are not well-understood. To 
decipher these mechanisms, we developed a system 
of cervico-vaginal tissue ex vivo to which HIV-1 is 
transmitted from semen under controlled laboratory 
conditions. Semen samples obtained from HIV-1-
infected and control men were analyzed for the 
presence of 21 cytokines, and HIV-1 transmission was 
simulated ex vivo by deposition on cervico-vaginal 
explants of virus suspended in semen or in PBS enriched 
with particular cytokines. In HIV-1-infected men, the 
cytokine spectrum was significantly changed, resulting 
in the establishment of new correlations and the 
strengthening of pre-existing correlations between 
different cytokines: HIV-1 infection increases the number 
of such correlations from 21 to 72. These changes in 
semen were local and different from ones in blood from 
the same individuals. One of the most upregulated 
seminal cytokines was IL-7, which enhanced replication 
of HIV-1 in cervico-vaginal tissue. This enhancement 
was associated with the suppression of apoptosis as 
evaluated from the expression of apoptotic markers, a 
decrease in the depletion of infected cells as evaluated 
from flow cytometry, and an increase in cell cycling as 
evaluated from Ki67 staining. 
In conclusion, HIV-1 establishes new strong correlations 
between various cytokines, thus imposing a high 
rigidity on their network that may contribute to the 
impaired capacity of the immune system to respond to 
microbial challenges. Seminal cytokines, in particular 
IL-7, may be key determinants of HIV-1 transmission 
from men to their uninfected female partners through 
vaginal intercourse and may become a new target for 
preventive and therapeutic strategies.
125
Progress Toward A Cure for HIV
Alain Lafeuillade
General Hospital, Toulon, FR
Combined antiretroviral therapy (cART) has dramatically 
increased life expectancy during HIV infection but must 
be taken life-long. Consequently, it carries problems 
of compliance, resistance, toxicity and cost. Finding a 
cure against HIV would resolve these issues. In theory, it 
could be either a “functional” or a “sterilizing” cure, but 
its main goal would be to keep HIV replication at bay 
without continuing cART. A couple of situations already 
exist where this has been achieved:
-The Berlin patient who is free of cART more than 5 
years following an allogenic bone marrow transplant 
from a donor with the delta 32 mutation on the CCR5 
gene;
-The “Mississippi child” who received cART within 31 
hours after birth;
-The “VISCONTI” patients who received cART at acute 
HIV infection and remained aviremic when this therapy 
was stopped a few years later;
-Two patients who received allogenic stem cell 
transplantation for lymphomas and have no trace of 
HIV, although cART is still continued.
Developing therapeutic strategies toward a HIV cure 
needs a deep understanding of the mechanisms that 
allow HIV persistence in reservoirs despite cART. Using 
current knowledge, approaches trying to purge the HIV 
reservoir have reached clinical trials using vorinostat. 
These trials showed the need of more potent activators 
combined with an immunologic intervention to 
eliminate cells where latent HIV has been activated. 
However, as the HIV reservoir is probably more complex 
than initially thought, others strategies than reactivation 
have to be pursued, including gene therapy.
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Questions and challenges in HIV drug 
resistance: A molecular perspective
Luis Menéndez-Arias
Centro de Biología Molecular “Severo Ochoa” (CSIC-
UAM), ES
The introduction of potent combination therapies in the 
mid-90s had a tremendous impact on AIDS mortality.  
However, drug resistance has been a major factor 
contributing to antiretroviral therapy failure.  At present, 
reverse transcriptase (RT) inhibitors constitute the 
backbone of successful antiretroviral therapies.  The HIV-
1 RT is a heterodimer composed of subunits of 560 and 
440 amino acids. Mutations in the RT-coding region 
selected during treatment with nucleoside RT inhibitors 
(NRTIs) confer resistance by altering discrimination 
between NRTIs and natural substrates (dNTPs), or 
by conferring a phosphorolytic activity (dependent 
on pyrophosphate or ATP) that unblocks the chain-
terminating inhibitor from the 3´ end of the DNA that 
is being synthesized.  The most relevant mutations 
conferring resistance to RT inhibitors map within the 
DNA polymerase domain of the RT (first 260 residues), 
and this region is subjected to genotypic analysis in 
order to select the proper antiretroviral treatment.
Despite the reasonable knowledge of the correlates 
between HIV genotype and the virological response 
to current therapies, our knowledge is still incomplete.  
The effects of antagonistic mutations and amino acid 
substitutions outside the DNA polymerase domain of 
the RT have been poorly characterized and examples 
will be given to illustrate the complexities of mutational 
patterns involved in resistance.  In addition, I will 
provide examples of epistatic effects of HIV-1 protease 
and RT mutations that could affect viral fitness.  
Finally, an overview of mutational pathways and 
mechanisms of resistance to novel antiretroviral drugs 
(e.g. raltegravir, elvitegravir, etravirine, rilpivirine and 
maraviroc) will be briefly presented. 
127
Safety, pharmokinetics and efficacy of VM-
1500, a novel reverse transcriptase inhibitor, 
In healthy volunteers and HIV-infected 
patients
Vadim Bichko, M.D.
Viriom Ltd. (Russia)
No abstract provided.
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Cure of HBV infection:  can APOBEC3 
deaminases mediate it?
Ulrike Protzer
Technische Universität München / Helmholtz 
Zentrum München, DE
Current antivirals cannot efficiently control but not 
eliminate hepatitis B virus (HBV) in the 300 million 
carriers at risk to develop liver diseases and cancer, 
because HBV establishes a stable nuclear cccDNA in 
infected hepatocytes. Interferon can clear HBV but 
therapeutic dosing is limited by side effects. We found a 
mechanism by which nuclear viral DNA can specifically 
be degraded. In HBV-infected cells and primary 
human hepatocytes, human liver-needle biopsies and 
in vivo mouse models, interferon and even at much 
lower doses lymphotoxin- -receptor activation 
up-regulated nuclear APOBEC3 family deaminases. 
Cytidine-deamination resulted in apurinic/apyrimidinic 
site formation and finally cccDNA degradation. No 
deamination was detected in genomic DNA since 
HBV-core protein targeted the APOBEC3 protein to 
cccDNA. Inducing nuclear APOBEC3 deaminases e.g. 
by triggering the lymphotoxin- -receptor pathway 
will be of high interest for the development of new 
therapeutics. The combination with existing antivirals 
shows great promise to eliminate the virus in chronic 
hepatitis B.
129
Polio Vaccines: The Past, Present and the 
Future
Konstantin Chumakov
FDA Office of Vaccines Research and Review, US
Inactivated Polio Vaccine (IPV) and live Oral Polio 
Vaccine (OPV) are among the most successful and 
widely used vaccines in the history of medicine. The 
history of their development and subsequent evolution 
in response to changing epidemiological and socio-
economic circumstances will be reviewed along with 
new efforts to develop a new generation of polio 
vaccines. OPV was responsible for virtual elimination 
of the disease, and its worldwide eradication may be 
achieved in few years.  Paradoxically, this monumental 
accomplishment demands introduction of a new 
generation of vaccines specifically designed for the 
new polio-free world to ensure the lasting success of 
the eradication campaign. Both current vaccines have 
their strengths and weaknesses: OPV is inexpensive 
and easy to administer, but its virus can revert to 
virulence and cause paralytic disease. IPV is highly 
efficient and safe but is more expensive, requires 
several intramuscular injections, and does not induce 
fully adequate mucosal immunity. New vaccines must 
combine the best characteristics of both. Lower cost of 
IPV and broader immune response could be achieved 
by using adjuvants, alternative routes of administration, 
and increasing production yield. Production of IPV 
is associated with biosecurity concerns because it is 
made from highly virulent strains. Novel approaches 
to reduce virulence of strains used for IPV manufacture 
will be discussed. Development of a more genetically 
stable OPV is underway by attempting to reduce rates 
of mutations and recombination. Polio vaccines were 
a paradigm for many other vaccines, and lessons 
learned from their evolution could help develop other 
prophylactic products.
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130  
Reinhard Kurth Honorary Lecture
HTLV-I and Adult T Cell Leukemia/
Lymphoma (ATLL) : Cellular and Molecular 
Basis of Transformation
William W Hall, Hirofumi Sawa and Hideki Hasegawa
University College, Dublin, IE; Hokkaido University, 
Sapporo, JP; National institute of Infectious Diseases, 
Tokyo, JP
HTLV-I infection is endemic in a number of well defined 
geographical regions and is associated with the 
development of ATLL, an aggressive T cell malignancy. 
While the pathogenesis of ATLL is incompletely 
understood, the viral regulatory and oncoprotein Tax is 
considered to play a central role. To better understand 
the role of Tax and to develop animal models of  
disease we have generated transgenic mouse models 
which have remarkably reproduced the clinical, 
pathological, hematological and molecular features of 
human disease. Studies on the latter have highlighted 
the important role of chemokines in the infiltrative and 
migratory properties of malignant cells, allowed the 
identification of specific cellular signalling pathways 
involved and the employment of specific inhibitors as 
treatment modalities. Treatment responses however 
have been limited and this can be attributed to the 
presence of cancer stem cells (CLCs). We will describe 
the identification and characteristics of the CLCs and 
demonstrate their important role in disease progression. 
In addition we will summarise studies employing 
proteomic approaches to identify unique CLC protein 
expression profiles which may serve as important 
targets towards eradicating the CLC population and 
which might  serve as key therapeutics.
131 
Replication and assembly of filoviruses
Larissa Kolesnikova, Gordian Schudt, Olga Dolnik, 
and Stephan Becker 
Institut für Virologie, Philipps-Universität 
Marburg, DE
The family of Filoviridae comprises Marburg and Ebola 
virus which both cause severe life-threatening diseases 
characterized by high fever, rash, thrombocytopenia 
and hemorrhagic diathesis. The pathogenesis of the 
syndrome is not completely understood; probably 
the dynamic replication of filoviruses in the infected 
host leads to an uncoordinated immune response. 
Detailed understanding of the basic mechanisms of 
filoviral assembly and interaction with host cells is 
key to identify targets of antiviral intervention. The 
first sign of filovirus replication that can be detected 
microscopically in the infected cell is the formation of 
inclusions in the perinuclear region. Inclusions contain 
all filoviral nucleocapsid proteins (NP, VP35, VP30, 
VP24, and L) but also the matrix protein VP40 and a 
number of cellular proteins. Viral nucleocapsids are 
formed within the inclusions by specific interactions 
among the viral proteins. Mature nucleocapsids 
are transported across the cytoplasm to the plasma 
membrane with the help of the actin cytoskeleton. In 
the cell periphery nucleocapsids are associated with 
the matrix protein and channeled into filopodia, the 
site of filoviral release. Nucleocapsids inside filopodia 
are cotransported together with the unconventional 
motor protein myosin 10. Transport of nucleocapsids 
and release of viral particles is supported by the cellular 
ESCRT machinery. 
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A Novel Pathway of Proviral HIV-1 Latency 
Regulated by Aminoacid Starvation and 
HDAC4
Guido Poli, Elisa Vicenzi, Maria Vittoria Schiaffino 
and Carine Van Lint
Vita-Salute San Raffaele University and Scientific 
Institute, IT
An intrinsic property of all retroviruses is their capacity 
to establish a state of latent infection in addition to 
active viral replication. Both genetic and epigenetic 
factors contribute to silence the integrated provirus 
and are nowadays targets of experimental approaches 
aiming at reactivating virus expression in order to 
kill the infected cells either by immune-mediated 
mechanisms (such as CTL) or by pharmacological 
agents. We have recently uncovered an unsuspected 
pathway triggered by essential aminoacid starvation 
and involving the downregulation of HDAC4, a class II 
HDAC, leading to a significant uprising of latent HIV-
1 infection in chronically infected cell lines, such as 
ACH-2 cells, expressing this enzyme, but not in similar 
cell lines, such as U1, negative for HDAC4 expression. 
Both pharmacological targeting of HDAC4 and siRNA-
mediated downregulation of its expression gave the 
same result. A similar phenomenon was observed for 
heterologous transgenes, driven by different promoters, 
introduced for gene therapy purposes, but not for their 
endogenous counterparts. This observation suggests 
that the mTOR-independent pathway triggered by 
aminoacid starvation and involving HDAC4 modulation 
represents or contributes to an intracellular response 
to foreign nucleic acids (I. Palmisano et al., PNASPlus 
2012). More recent results with a broader variety of 
HIV-1 latency models will be discussed.
133
Structural basis for ebolavirus matrix 
assembly and budding; protein plasticity 
allows multiple functions
Zachary Bornholdt, Takeshi Noda, Dafna Abelson, 
Peter Halfmann, Malcolm Wood, Yoshihiro Kawaoa, 
Erica Ollmann Saphire
The Scripps Research Institute, California, US
Proteins, particularly viral proteins, can be 
multifunctional, but the mechanism(s) behind this 
trait are not fully understood. Here, we illustrate 
through multiple crystal structures, biochemistry and 
cellular microscopy that the Ebola virus VP40 protein 
rearranges into different structures, each with a distinct 
and essential function required for the ebolavirus life 
cycle. A butterfly-shaped VP40 dimer trafficks to the 
cellular membrane. There, electrostatic interactions 
trigger rearrangement of the polypeptide into a linear 
hexamer.  These hexamers construct a multi-layered, 
filamentous matrix structure that is critical for budding 
and resembles tomograms of authentic virions. A third 
structure of VP40, formed by a different rearrangement, 
is not involved in virus assembly, but instead uniquely 
binds RNA to regulate viral transcription inside infected 
cells. These results provide a functional model for 
ebolavirus matrix assembly and the other roles of VP40 
in the virus life cycle, and demonstrate how a single, 
wild-type, unmodified polypeptide can assemble into 
different structures for different functions. 
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A cellular restriction factor blocking 
replication of an emerging bunyavirus in 
human cells: clues for cross-species barriers?
Mariana Varela, Ilaria Piras, Angela McLees, Catrina 
Mullan, Frederick Arnaud, Xiaohong Shi, Esther 
Schnettler, Alain Kohl, Richard Elliott and 
Massimo Palmarini
MRC-University of Glasgow Centre for Virus 
Research, UK
Schmallenberg virus (SBV) is a novel orthobunyavirus 
of ruminants that emerged in Europe in the summer 
of 2011.  Although mild clinical signs are observed 
in infected adult animals, transplacental infection has 
been associated with the development of congenital 
malformations, stillbirths and abortions. SBV has spread 
dramatically across north-western Europe reaching 
100% prevalence in some herds. Despite antibodies 
against SBV being found in a variety of animal species 
neither human cases nor positive serology in highly 
exposed humans have been detected. 
We have recently developed molecular and serological 
tools, and an experimental in vivo model as a 
platform to study SBV pathogenesis, tropism and 
virus-host cell interactions. Specifically we developed 
a reverse genetics system that aided us in unraveling 
determinants of virulence.
Here, we report identification of a cellular factor that 
restricts SBV replication. While the human orthologue 
restricts SBV replication under different experimental 
conditions, no restriction is observed by the ovine 
counterparts. We show that the restriction is specific 
since SBV replication is restored under the presence of a 
known viral restriction factor antagonist. We also show 
that this viral restriction factor and SBV nucleocpasid 
co-localize at the cell membrane and in the perinuclear 
region and we partially unravel the mechanism of 
restriction. Based on these results we hypothesize 
that the lack of positive human serology to SBV is 
related to the ability of this cellular factor to restrict 
SBV replication and we are currently exploring if these 
findings can be extended to other bunyaviruses. 
135
HIV-associated immunodeficiency despite 
potent antiretroviral therapy with CD4 T cell 
reconstitution
Bhawna Poonia, Suchita Chaudry, Haishan Li, 
Cristiana Cairo and C. David Pauza
Institute of Human Virology, University of Maryland 
School of Medicine, US
CD4 T cell reconstitution in patients with HIV is associated with 
increased responses to conventional vaccines and improved 
resistance to opportunistic infections. However, prolonged 
therapy fails to replenish a capacity for immune control over 
HIV and patients who interrupt therapy inevitably rebound 
to pre-treatment viral burden in plasma.  Only elite patients, 
termed NVS or natural virus suppressors (1), control viremia to 
undetectable levels in the absence of therapy. Our earlier studies 
on NVS patients showed that this group was distinguished from 
all other HIV patients by the presence of normal levels of CD56+ 
Vи2Vи2 T cells in blood (2) reflecting reconstitution of the T cell 
receptor repertoire through new cell synthesis (3). The CD56 
marker identifies cytotoxic effector lymphocytes including NK, 
CD8,иии T and NKT subsets, but it’s function remains unknown. 
We have now shown persistent depression of CD56 expression 
on CD8 T cells from HIV+ individuals except for NVS patients 
where the levels approach those found in normal controls. 
The CD56+ CD8 T cell subset is highly responsive to stimulus, 
expresses high levels of perforin/granzyme and the small 
population remaining in HIV patients on therapy, also express 
the immune exhaustion marker TIM-3, indicating cells may be 
lost through an apoptosis mechanism. The persisting defect 
in CD56 expression for two T cells subsets is consistent with a 
lack of cytolytic effector function and is present in patients with 
complete virus suppression for many years due to treatment, 
long after the T cell population is refreshed by new cell synthesis. 
The block to lytic effector function may explain why treated 
patients fail to eradicate viral reservoirs; this mechanism is a key 
target for new therapies designed to cure HIV disease. 
1. M. M. Sajadi, A. Heredia, N. Le, N. T. Constantine, R. 
R. Redfield, HIV-1 natural viral suppressors: control of viral 
replication in the absence of therapy. AIDS 21, 517 (2007).
2. D. J. Riedel et al., Natural viral suppressors of HIV-1 have a 
unique capacity to maintain gamma delta T cells. AIDS 23, 1955 
(2009).
3. S. Chaudhry, C. Cairo, V. Venturi, C. D. Pauza, The gamma 
delta T cell receptor repertoire is reconstituted in HIV patients 
after prolonged antiretroviral therapy. AIDS epub ahead of 
print, (2013).
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HIV-1 Nef regulates activity of endoplasmic 
reticulum chaperone calnexin
Lucas Jennelle1, Ruth Hunegnaw1, Larisa Dubrovsky1, 
Tatiana Pushkarsky1, Michael L. Fitzgerald2, Dmitri 
Sviridov3, and Michael Bukrinsky1*
1Department of Microbiology, Immunology and 
Tropical Medicine, George Washington University, 
Washington, DC 20037, USA; 2Lipid Metabolism 
Unit, Massachusetts General Hospital, Harvard 
Medical School, Boston, MA 02114, USA; 3Baker IDI 
Heart and Diabetes Institute, Melbourne, Victoria 
3004, Australia. 
HIV-1 Nef promotes viral replication by downmodulating 
a number of cell surface transmembrane proteins, such 
as CD4, MHC-I and MHC-II, which are targeted by Nef 
to various degradation pathways.  Nef is also responsible 
for downregulation of cellular cholesterol transporter 
ABCA1, and this effect contributes to development of 
atherosclerosis in HIV infected patients.  Surprisingly, in 
contrast to CD4 and MHC I, to which Nef has to bind to 
exert downregulation, binding to ABCA1 turned out to 
be unnecessary for inactivation of ABCA1 by Nef.  Here, 
we identified a novel mechanism by which Nef influences 
activity of host cell and viral proteins.  We show that 
Nef interacts with an endoplasmic reticulum chaperone 
calnexin, which is essential for folding and maturation of 
glycosylated proteins.  Nef disrupts calnexin interaction 
with ABCA1, thus impairing functionality of this protein, 
but increases affinity and enhances interaction of calnexin 
with gp160, promoting maturation and functionality 
of viral Env proteins.  Knock-down of calnexin lead to 
reduced fusion activity of HIV-1 envelope and reduced 
virion infectivity, as well as to defective cholesterol efflux, 
which is mediated by ABCA1.  However, gp160 and 
ABCA1 interacted with calnexin differently: while gp160 
binding to calnexin was dependent on glycosylation, 
interaction of ABCA1 with calnexin was glycosylation-
independent.  Therefore, Nef binds to calnexin and 
stimulates interaction between calnexin and gp160 at the 
expense of ABCA1 and probably other ER proteins.  These 
results provide a mechanistic explanation for previously 
unexplained effect of Nef on functionality of ABCA1, and 
suggest a mechanism for upregulation of HIV infectivity by 
Nef through stimulation of Env maturation.
137
Interplay between host defenses and viral 
anti-defenses as a major factor of viral 
cytopathogenicity
Vadim I. Agol
M.P.Chumakov Institute of Poliomyelitis and Viral 
Encephalitides, Russian Academy of Medical Sciences 
and A.N.Belozersky Institute of Physical-Chemical 
Biology, Moscow State University, RU
The prevailing paradigm posits that virus-induced cellular 
injuries (cytopathic effect, CPE) are caused by hijacking 
of cellular substrates, energy, and infrastructure by the 
pathogens for the needs of their reproduction. However, 
this appears to be not the sole, and even not the most 
important, mechanism of cellular pathology triggered by 
viral infections. There is ground to believe that the most 
severe harm may come not from viral reproduction as 
such but rather from (miscalculated) host defenses as well 
as from viral anti-defensive activities. The experiments to 
be presented strongly support this notion. By using as 
a model system HeLa cells infected with mengovirus (a 
strain of encephalomyocarditis virus, a lytic picornavirus), 
we show that the major signs of CPE caused by this 
virus can be uncoupled from its reproduction. This can 
be achieved by partial mutual disarmament of the virus 
(by mutational inactivation of one of its anti-defensive 
“security” proteins, the leader protein) and the host 
(by chemical inhibition of one of its defensive innate 
immunity mechanisms, apoptosis). Under such conditions, 
the appearance of major cellular injuries is postponed 
until well after the completion of the viral reproduction. 
Remarkably, a more profound disarmament of the virus 
(by additional deletion of its second security protein, 
2A) accompanied with a marked suppression of the 
viral reproduction leads to a faster death of the infected 
apoptosis-deficient cells due primarily to their defensive 
suicidal programmed necrosis. Thus, efficient strategies 
to ameliorate virus-induced injuries may include measures 
aimed at suppression of not only viral reproduction or viral 
anti-host functions but also of host defenses
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Understanding protective immunity: 
Lessons from measles
Wen-Hsuan Lin and Diane E. Griffin
Johns Hopkins Bloomberg School of Public 
Health, US
Measles is the poster child for establishment of life 
long immunity to re-infection.  This is associated with 
a prolonged persistence of measles virus (MeV) RNA 
in blood and lymphoid tissue. The live attenuated 
vaccine is also effective, but the immune responses 
are less robust and of somewhat shorter duration than 
after natural infection. Through study of a variety of 
experimental DNA and virus-vectored vaccines in 
rhesus macaques followed by wild type MeV challenge, 
we have identified 4 levels of protective immunity: 1) 
protection from both rash and viremia; 2) protection 
from rash, but not viremia; 3) protection from rash 
and viremia, but not infection; 4) no protection with 
possibility of enhanced disease.  Protection from rash 
requires high levels of high avidity MeV neutralizing 
antibody, but this is not sufficient to protect from 
viremia. MeV-specific T cells alone do not protect from 
rash or viremia, but lead to more rapid clearance of 
MeV RNA from blood. Antibody and T cell responses 
to the hemagglutinin (H) and fusion (F) surface 
glycoproteins protect from rash and viremia, but not 
infection leading to late appearance of viral RNA in 
blood.  Parenteral or deep lung respiratory delivery of 
the live virus vaccine protects against rash, viremia and 
infection.  Further studies are needed to determine 
if experimental vaccines require additional antigens 
or induction of a different type of immune response 
to recapitulate the protection provided by the live 
attenuated vaccine virus and natural infection.
139
Dengue vector control:  critical needs and 
opportunities for helping to control the 
dengue pandemic
Barry Beaty
Department of Microbiology, Immunology, and 
Pathology, Colorado State University, US
Aedes aegypti mosquito control is currently the only 
option for controlling and preventing epidemic dengue 
and dengue hemorrhagic fever.  However, current 
approaches for vector control are not stemming the 
rising tide of dengue disease throughout the tropical 
world.  In the absence of a vaccine, new and effective 
approaches are needed to improve vector control. 
Novel  approaches to prevent dengue virus transmission 
will be described and discussed, including 1) the Casa 
Segura approach to prevent dengue transmission 
in the home, 2) development of a new generation 
of molecular mosquitocides to address the rise of 
resistance to existing insecticides, and 3) engineering 
dengue virus resistant mosquitoes.  There is a public 
health imperative to increase the armamentarium for 
vector control.
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Reversing the Epidemic of HIV-1C in 
Southern Africa with Treatment as 
Prevention
M. Essex
Harvard School of Public Health, US
The epidemic of HIV-1C in southern Africa is 
characterized by a sustained prevalence that is 
substantially higher than for other epidemics of HIV/
AIDS. Perhaps the best correlate of transmission is 
high viral load (HVL), which we target to prevent 
spread of HIV in a community randomization 
trial based on antiretroviral treatment (ART) as 
prevention (TasP). Designed for over 100,000 adults 
in 30 randomized villages in Botswana, this trial 
also utilizes other prevention interventions such as 
HIV testing, male circumcision, clinical linkage and 
ART chemoprophylaxis during pregnancy. Viral 
phylogenetics is used to estimate the proportion of 
incident infections originating in test villages, and 
thus the relative contribution of TasP for preventing 
transmissions. Analysis of results through modeling 
includes estimating cost effectiveness and estimations of 
contributions for different prevention interventions. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
141
Gene Discovery and Data Sharing in 
Genome Wide Association Analyses: lessons 
form AIDS genetic restriction genes
Stephen J O’Brien, Anton Svitin,  Sergey Malov, 
Nikolay  Cherkazov  Pavel Dobrynin, Paul Geerts, 
Jennifer Troyer, Sher Hendrickson-Lambert, Efe 
Sezgin, Holli Hutcheson,
Theodosius Dobzhansky Center for Genome 
Bioinformatics, St. Petersburg  State University (RU)
As genome wide association studies plus whole 
genome sequence analyses  for complex human 
disease determinants are expanding, it  seems useful  
to develop strategies to facilitate large data sharing, 
rapid replication and validation of provocative  
statistical associations that straddle the threshold 
for  genome wide significance. At this conference, 
we  shall announce GWATCH, (Genome Wide 
Association Tracks Chromosome Highway) a web 
based data release platform that can freely display 
and inspect unabridged  genome tracked association 
data without compromising privacy or Informed 
Consent constrictions, allowing for rapid discovery 
and replication opportunities. We illustrate the utility 
with HIV-AIDS resistance genes screened in combined 
large multicenter cohort studies  GWAS (MACS, HGDS, 
MHGS, ALLIVE , LSOCA HOMER) developed and 
studied over the last decades.
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Sochi virus as a highly pathogenic and 
life-threatening agent
E.Tkachenko, T.Dzagurova, B.Klempa, D.Kruger
Chumakov Institute of Poliomyelitis and Viral 
Encephalitides, Moscow, RU; Institute of 
Virology, DE
A new genotype of Dobrava-Belgrade virus (DOBV), 
Sochi virus, was found in the Black Sea field mouse, 
Apodemus ponticus. This mouse is naturally occurring 
in the Southern European Russia and transcaucasian 
countries between the Black and the Caspian Sea. 
Recently, cell culture isolates of Sochi virus have been 
generated from A. ponticus and an HFRS patient with 
fatal outcome.
At the present state of knowledge, Sochi virus seems 
to be the most dangerous representative of DOBV. 
Virus diagnostics in patients was accomplished by 
immunofluorescence assay, serotyping of neutralizing 
antibodies, and RT-PCR amplification of viral genome 
segments. In phylogenetic analyses we found a spatial 
clustering of the viral nucleotide sequences derived 
from patients and mice trapped at different localities of 
the Russian Black Sea coast region demonstrating Sochi 
virus as the causal pathogenic agent in humans. 
We currently oversee in detail the clinical courses of 
51 patients with confirmed Sochi virus infection. The 
case fatality rate was determined to be as high as 14%. 
Nearly 60% of clinical courses were defined as severe 
(including deaths) and nearly 40% as moderate. Four 
times more males than females were affected. Quite 
unusual for hantavirus disease, also young people 
became ill due to Sochi virus infection; 10% of patients 
were found between 7 and 15 years old and the age 
average of all patients was not much higher than 30 
years.
There is an urgent need to monitor the epidemiology 
of the new virus - not only because of its health-
threatening character in this particular geographical 
area but also because of its potential ability to overcome 
host species barriers. Colonization of nearly related 
host species, as A. flavicollis or A. sylvaticus, by the virus 
could dramatically increase its geographical spread 
and consequently further enhance the danger for the 
human population.  
143 
Rift Valley fever virus: A virus with potential 
for global emergence
Janusz T. Paweska
Center for Emerging and Zoonotic Diseases, 
National Institute for Communicable Diseases of the 
National Health Laboratory Service, ZA
The capacity of Rift Valley fever virus (RVFV) to spread 
into new territories by crossing significant natural 
geographic barriers, re-emerge in endemic regions 
after long periods of silence to cause large outbreaks in 
human and animal populations constitute a formidable 
challenge for public and veterinary health authorities 
as well as for scientific communities worldwide. In spite 
of recent advances in research on RVFV pathogenesis, 
molecular epidemiology, outbreak prediction, 
development of new diagnostic tools and vaccines, 
some fundamental aspects of the epidemiology and 
ecology of the virus remain elusive. Large outbreaks 
of RVF are associated with anomalous high rainfalls 
leading to massive flooding and the resultant swarms of 
competent mosquito vectors transmitting the virus to a 
wide range of susceptible vertebrate species. However, 
the exact mechanism of RVFV natural transmission 
during interepizootic periods remains largely unknown, 
including the postulated long-term virus persistence 
in transovarially infected eggs of floodwater Aedes 
mosquito species, and the role of wild mammals as 
reservoirs. The presence of competent mosquito vectors 
in countries free of RVF, the wide range of mammals 
susceptible to the virus, the global changes in climate, 
and increased animal trade and travel are some of the 
factors which might contribute to international spread. 
This presentation provides the background to the major 
outbreaks, molecular biology and epidemiology of 
RVFV, and overviews aspects of ecology, host and vector 
range which make the virus a potential global emerging 
threat.
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Viral/bacterial mixed infections transmitted 
by ticks: Diagnosis and prevention in Russia
Korenberg, E. I.
Gamaleya Scientific Research Institute of 
Epidemiology and Microbiology of the Health 
Ministry of the Russian Federation, RU 
No abstract provided. 
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Arbovirus and related infection disease in 
China
Guodong Liang
National Institute for Viral Disease Control and 
Prevention, China CDC
Arboviruses (arthropod-borne viruses) are maintained 
in nature in cycles involving hematophagous 
arthropod vectors such as mosquitoes, midges, ticks 
and susceptible vertebrate hostsиhuman or animals. 
At present, more than 550 arboviruses have been 
identified, among which are more than 130 virus 
species that can cause disease in susceptible vertebrate 
hosts. Today, Dengue fever, West Nile virus disease, 
and Rift valley fever etc. still outbreak in the worldwide. 
Study of arboviruses not only becomes the important 
topics of virology, but also appears to be a social 
problem directly related with the public health.
Japanese Encephalitis Virus (JEV), Dengue Virus (DENV), 
Crimean-Congo Hemorrhagic Fever Virus (CCHFV) (also 
known as Xinjiang Hemorrhagic Fever Virus in Chinese, 
XHFV), and Tick-Borne Encephalitis Virus (TBEV) are the 
four principal arboviruses of public health importance in 
mainland China at present. 
There is a growing body of evidence indicating that 
other arboviruses are present and causing human 
infections and disease in China. Over the past years, an 
investigation of arbovirus has been carried out in China, 
across the country, to learn more about arboviruses, 
or viruses spread by insects. The various specimens 
with a total number of 897, 369 have been collected 
from 29 provinces of mainland China, including 841, 
576 mosquitoes, 16, 315 ticks, 5, 968 sandflies, 960 
midges, 436 bats, 2, 309 animal specimens, 18, 579 
clinical specimens from patients with fever and viral 
encephalitis and 13, 380 serum specimens from healthy 
populations. Total 512 arbovirues strains, belonging 
to 23 species in 10 genuses of 7 families, were isolated 
from various specimens, including Flavivirus, Alphavirus, 
Bunyavirus, dsRNA virus and DNA virus have been 
identified. 
 
Abstracts15th Annual International Meeting of the Institute of Human Virology 62
INTERNATIONAL MEETING
1
5
T
H
 
A
N
N
U
A
L
Institute of Human Virology in partnership with 
the Global Virus Network and The Moscow 
Center for HIV/AIDS Prevention and Treatment
SEPTEMBER 8 –12, 2013  |  MOSCOW
CONTENTS SPEAKER SCHEDULE EVENTS SCHEDULE
1
5
T
H
 
A
N
N
U
A
L
ABSTRACTS INDEX
 
146
Understanding the pathogenesis of prion 
and surveillance for human prion diseases in 
China
Xiao-Ping Dong
National Institute for Viral Disease Control and 
Prevention, China CDC
Through human prion disease cases, infectious 
animal models, cell models and prion proteins, the 
neuropathological and pathogenic characteristics 
of prion diseases, the cytotoxicity of pathological 
prion, the conversion and replication of prion and 
the infectivity of prion strains were  comprehensively 
evaluated. With the established specimen bank of 
human and experimental prion diseases, several 
potential methodologies for diagnosis have been set up. 
Recently, high sensitive tools, e.g. PMCA and RT-QuIC, 
have been established. Since 2006, a national CJD 
surveillance has been conducted, covering 12 provinces 
in mainland China. The epidemiological, clinical 
and laboratory features of Chinese CJD were firstly 
described. Dozens of Chinese genetic prion diseases 
have been firstly identified.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
147
Globalization and New Challenges Caused 
of Communicable Diseases
Saulius Chaplinskas, MD, PhD
Center for Communicable Diseases and AIDS, LT
No abstract provided. 
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HPV, HIV, and Cancer: A Global Challenge
Silvia Franceschi
The seminal discovery that human papillomavirus 
(HPV) infection causes cervical cancer provides an 
opportunity for prevention by vaccination and new 
screening approaches.  Approximately 600,000 new 
cancer cases per year are attributable to HPV worldwide 
of which about half million in less developed countries 
(de Martel et al, Lancet Oncology, 2012). These cancers 
include all cervical cancers, the vast majority of anal 
cancers and approximately half of cancers of the vulva, 
vagina, and penis. In the head and neck, HPV is clearly 
involved in a fraction of cancer of the oropharynx that 
varies between 10% and 70% by geographic area and 
the burden of cancer caused by tobacco use.  Most 
HPV infection is harmless and clears spontaneously but 
persistent infection with high risk HPV (notably type 
16) is one of the most powerful human carcinogens. 
HPV disrupts normal cell cycle control promoting 
uncontrolled cell division and the accumulation of 
genetic damage.  Two effective prophylactic vaccines 
composed of HPV-16/18 and HPV-16/18/6/11 virus 
like particles have been introduced in many developed 
countries as a primary prevention strategy.  HPV testing 
is clinically valuable for secondary prevention in triaging 
low grade cytology and as a test of cure following 
treatment. More sensitive than cytology, primary 
screening by HPV testing could allow screening intervals 
to be extended. If these prevention strategies can be 
implemented in developing countries, many thousands 
of lives could be saved. HIV-positive individuals are 
at increased risk of HPV infection and cancer sites 
associated with HPV. cART and cervical screening may 
avoid an increase in cervical cancer in sub-Saharan 
cancer. 
 
 
 
 
 
 
 
 
 
149
HCV AND lymphoma: Genetic and 
epigenetic factors
Zignego AL, Gragnani L, Fognani E, Piluso A
Center for Systemic Manifestation of Hepatitis 
Viruses- University of Florence, IT
Over 180 million people worldwide are chronically 
infected with the hepatitis C virus (HCV). HCV infection 
is a major cause for hepatocellular carcinoma (HCC), 
moreover the association with B-cell lymphoproliferative 
disorders (LPDs) like mixed cryoglobulinemia (MC) or 
B-cell non-Hodgkin lymphoma (B-NHL) is undisputed.
The mechanisms by which HCV contributes to LPD 
development are still poorly understood. Available 
data suggest that the viral infection may induce LPDs 
through a multifactorial and multistep process that 
involves the sustained activation of B cells, the abnormal 
and prolonged B cell survival, and genetic and/or 
epigenetic factors.
Concerning genetic factors, different authors reported 
an association between specific HLA clusters or B-cell 
activating factor promoter genotype and a higher risk 
of developing MC and lymphoma. In addition, the 
results of a large, ongoing genome wide association 
study (GWAS) will probably allow the identification of 
specific genetic profile of HCV patients with LPDs.
Furthermore, microRNAs (miRNAs) can give a major 
contribution to the pathogenesis of several neoplastic, 
lymphoproliferative diseases and it is conceivable their 
involvement in the pathogenesis of HCV-related LPDs. 
We recently showed that specific miRNAs were 
differently modulated in PBMCs from HCV patients who 
developed MC and/or NHL. In addition, HCV patients 
who developed HCC, showed a differential miRNAs 
regulation. 
In conclusion, available data suggest that the genetic/
epigenetic analysis of HCV-related cancerogenesis is of 
great usefulness in both the pathogenetic and clinical/
translational areas possibly allowing the definition of 
diagnostic/prognostic markers for early detection of 
lymphatic or hepatic cancer. 
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Carcinogenesis of HPV
Buonaguro FM, Tornesello ML, Annunziata C, 
Buonaguro L 
Istituto Naz. Tumori – IRRCS 
“Fondazione G. Pascale,” IT
Human papillomavirus are oncogenic DNA virus able 
to transform cutaneous and mucosal epithelial cells. 
The most relevant transforming mechanisms is the 
down-regulation of two oncosuppressor genes: p53 
and pRb. For their frequency of detection in invasive 
lesions some genotypes have been defined “high 
risk” and their carcinogenicity has been referred to 
(a) their capacity to induce persistent infections, for 
the efficacy to escape the host immune system, (b) 
the binding affinity of their E6/E7 oncoprotein to the 
respective oncosuppressors, and (c) their efficacy 
to induce genomic instability. In vivo risk of cancer 
progression, in particular transition from pre-invasive to 
invasive cancer lesions, and the subsequent frequency 
of developing metastatic lesions as well as responsivity 
to anticancer treatment, is due to specific virus-host 
interactions and genomic damages. As paradigm the 
better prognosis and higher responsivity to treatment 
of HPV-positive oropharyngeal cancers in comparison 
to HPV-negative cancers. Mutations in genes of 
the apoptotic pathway, particularly the TP53 gene, 
have been analyzed in cervical cancers. A significant 
higher mutation frequency of TP53 gene in the CAC 
adenocarcinoma (32 of 241; 13.3%) compared to SCC 
squamous cell carcinoma (39 of 657; 5.9%; P=0.0003, 
и(2) test) has been identified. Three codons (175, 248 
and 273) were the most commonly mutated in both, 
codon 249 mainly in SCC, codon 282 only in CAC. The 
G to A and C to T transitions were the prevalent type 
of mutations in both SCC and CAC (48.7% and 53.5% 
of all mutations, respectively). The frequency of C to 
A transversion was relatively high only in CAC (25%), 
while the mirror mutation G to T was comparatively 
frequent in SCC (14.6%). 
 
 
 
151
Using genomics to search for new viral 
causes and treatments for human cancer
Patrick S. Moore, Yuan Chang
American Cancer Society Professor, Cancer Virology 
Program, University of Pittsburgh Cancer Institute, 
Pittsburgh, PA, US
Although animal polyomaviruses, such as SV40, 
have been critical models in cancer research for 
over one-half century, polyomaviruses have not--
until recently--been linked to human cancer.  Using 
digital transcriptome subtraction, Merkel cell 
polyomavirus (MCV) was discovered in 2008 to 
infect most Merkel cell carcinomas, the most severe 
form of skin cancer.  Normally, MCV is an common 
and asymptomatic infection of the human skin.  In 
Merkel cell tumors, however, the virus integrates and 
undergoes mutations that eliminate viral replication but 
allow continued expression of viral oncogenes.  MCV 
and MCC reveal a new model for carcinogenesis 
in which a rare combination of xenomutations to 
healthy skin flora initiate a deadly cancer.  Using 
new sequencing technologies, the causes previously-
unsuspected viral cancers can be uncovered and clues 
for new rational drug therapies can be designed. 
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Insights into the pathogenesis of HHV8-
driven body cavity-based lymphoma
Maria Luisa Calabrò1, Laura Lignitto1,  Adriana 
Mattiolo1, Elena Negri1, Luca Persano2, Lisa 
Gianesello1, 
Luigi Chieco-Bianchi3
1Immunology and Molecular Oncology, Veneto 
Institute of Oncology, IOV - IRCCS, Padova, IT; 
2Department of Women’s and Children’s Health, 
University of Padova, Padova, IT:  3Department of 
Surgery, Oncology and Gastroenterology, University 
of Padova, Padova, IT
Human herpesvirus 8 is associated with the 
development of primary effusion lymphoma (PEL), an 
aggressive non-Hodgkin’s lymphoma characterized 
by the proliferation of the malignant lymphocytes 
almost exclusively in large serous cavities. The 
mechanisms involved in the preferential tropism for 
serous cavities and in the aggressive course of PEL 
remain to be fully clarified. To study the role of host 
microenvironment in PEL progression, we previously 
compared the antineoplastic activity of a murine 
interferon   -expressing lentiviral vector (mIFN-
-LV)  to that of a human IFN- -LV in a murine model 
of peritoneal PEL. We demonstrated that in vivo 
targeting of the murine microenvironment showed an 
antineoplastic activity comparable to that observed 
with the hIFN- -LV. These findings highlighted the 
relevant role of body cavity environment in PEL growth 
and indicated that modulation of microenvironment 
may impair PEL growth in vivo. By using cocultures of 
PEL cell lines with human mesothelial cells (HMC), we 
mimicked the interactions existing in body cavities to 
analyze the mechanisms involved in PEL progression. 
PEL cells induced a myofibroblastic morphology in 
HMC, paralleled by an expression profile indicative of 
the occurrence of epithelial-mesenchymal transition 
(EMT).  Moreover, HMC increased proliferation and 
resistance to apoptosis of PEL cells. These data indicate 
that PEL cells induce EMT in HMC and fibrosis of 
serous membranes.  In turn, HMC modulate PEL cell 
turnover, thus providing a milieu favorable to PEL 
progression. These findings open new perspectives into 
the mechanisms involved in PEL progression and may 
indicate new targets for PEL treatment. 
153
Molecular pathogenesis by HTLV-1 bZIP 
factor
Masao Matsuoka
Institute for Virus Research, Kyoto University, JP
Human T-cell leukemia virus type 1 (HTLV-1) mainly 
transmits by cell-to-cell contact. Therefore, this virus 
induces proliferation of infected cells to facilitate 
transmission. In HTLV-1 infected individuals, infected 
cells proliferate in vivo. This proliferation of infected cells 
leads to the development of adult T-cell leukemia (ATL) 
and inflammatory diseases including HTLV-1 associated 
myelopathy (HAM). HTLV-1 bZIP factor (HBZ) is 
consistently expressed in ATL cells and HTLV-1 infected 
cells, and plays a critical role in their proliferation. 
Transgenic expression of HBZ causes T-cell lymphoma 
and inflammatory diseases, indicating that HBZ is 
critical for the pathogenesis of HTLV-1. 
We analyzed the function of HBZ and found that it 
possessed opposite functions to Tax in many pathways. 
We found that Tax could activate the classical Wnt 
pathway while HBZ inhibited it by interacting with 
TCF1/LEF1. The canonical Wnt pathway is activated 
in the thymus, and its transcription factors, TCF1/
LEF1, suppressed the viral gene transcription by Tax. 
Conversely, the canonical Wnt pathway is suppressed in 
the peripheral T cells in which the non-canonical Wnt 
pathway is activated. HBZ enhanced the expression 
of Wnt5a, which is a ligand in non-canonical Wnt 
signaling. Knockdown of Wnt5a suppressed the 
proliferation and migration of ATL cells. Thus, activation 
of the non-canonical Wnt pathway by HBZ is linked 
with proliferation of ATL cells. 
These findings suggest that HTLV-1 is adapted to, not 
thymic T cells, but peripheral T cells. HBZ modulates 
the intracellular environment suitable for HTLV-1 
replication and proliferation of infected cells.
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Responding to the challenge of AIDS 
Associated Cancers in Nigeria
Dr. William Blattner and 
Clement Adebamowo
The stabilization of the HIV epidemic in Africa has uncovered new epidemic 
of HIV associated comorbidities including cancers which the poorly 
developed health care system, poor infrastructure and lack of personnel is 
unable to cope with. In November 2012, international leaders in Cancer 
Research and Policy from 15 countries met at the NIH, Bethesda and 
made recommendations about the interventions needed to respond to 
the global cancer challenge in the world. These include (a) Creation of 
reliable, population-based registries that define the incidence, mortality, and 
survival rates of different types of cancers (b) Implementation of prevention 
measures to mitigate factors now known to promote cancer—tobacco, 
certain infectious agents, ultraviolet radiation, alcohol, obesity, lack of 
exercise, and diet, (c) Screening individuals for certain cancers (of the cervix, 
breast, prostate, and colorectum, in particular) and (d) Optimal cancer 
treatment. In this presentation, I will highlight how the Institute of Human 
Virology, University of Maryland (IHV) and the Institute of Human Virology 
Nigeria (IHVN) working with partners in Nigeria and internationally have 
implemented these recommendations and present data illustrating the 
outcome of our interventions. For example, 
Since 2010, 21 cancer registries have been developed or re-strengthened 
in Nigeria and 3 of these have met the WHO criteria for population based 
cancer registration (PBCR). These registries are now able to contribute data 
to the global cancer incidence database after more than 30 years during 
which there was no data from Nigeria. With mainstreaming of an additional 
3 PBCR this year, we would have increased the proportion of Africa covered 
by PBCR from 11% to 32%. Our results also correct distortions in the 
estimates of cancer incidence and mortality in Nigeria which was previously 
based on projections derived from data from cancer registries of other 
African countries that had been used in the past
Cervical cancer is the commonest female cancer in Africa and in women 
living with HIV/AIDS. Implementation of screening programs has reduced 
incidence in developed countries by 80% in recent decades but incidence in 
developing countries remain stable or has been increasing. IHV implements 
an innovative “screen and treat” with immediate treatment with cold 
coagulation, digital cervicography for QA/QC and web based consultation 
for second opinion for early detection of cervical cancer. In collaboration 
with the Nigerian authorities and other partners, this program plans to reach 
1,000,000 Nigerian women with at least 1 lifetime screening event over the 
next 10 years. 
This screening project laid the foundation for the NIH funded African 
Collaborative Center for Microbiome and Genomics Research (ACCME), part 
of the Wellcome Trust and NIH funded H3Africa initiative, which we set up 
at the IHVN and is currently engaged in integrative epidemiology of cervical 
cancer that is exploring the host and viral genomics and epigenomics, 
somatic cervical cancer genomics as part of NIH led Cancer Genome Atlas 
mapping project (TCGA), vaginal microenvironment – innate immunity and 
vaginal microbiota, as well as detailed risk factor characterization of prevalent 
and persistent HPV infection. Preliminary results from early studies conducted 
at this Center will be presented. 
Because of dearth of systematic information about the epidemiology of 
AIDS Associated Cancers in Africa, we have created a matched prospective 
cohort of persons living with HIV/AIDS and healthy volunteers who are being 
followed up every 2 years with detailed clinical evaluation and collection 
of data and biological samples in order to improve knowledge of the 
epidemiology of HIV Associated Comorbidities and provide high quality 
biological samples for molecular and omics studies. In my presentation, I 
will also mention some of the trainings that we have conducted, research 
into other cancer risk factors and the work we are doing to map the 
infrastructural needs for oncology treatment in Nigeria.
155
Evolution by Tumor Neofunctionalization 
and Phenomenon of Tumor Specifically 
Expressed, Evolutionarily Novel (TSEEN) 
genes
Andrei P. Kozlov, PhD
The Biomedical Center, St. Petersburg (RU)
Earlier I formulated the hypothesis of the possible 
evolutionary role of tumors. This hypothesis suggests 
that tumors supply evolving multicellular organisms 
with extra cell masses for the expression of newly 
evolving genes. After expression of novel genes in 
tumor cells, tumors differentiate in new directions and 
give rise to new cell types, tissues and organs.
In the presentation, the bulk of data supporting the 
positive evolutionary role of tumors will be reviewed, 
obtained both in the lab of the author and from the 
literature sources.
The following issues will be addressed: the widespread 
occurrence of tumors in multicellular organisms; 
features of tumors that could be used in evolution; 
the relationship of tumors to evo-devo; examples 
of recapitulation of some tumor features in recently 
evolved organs; the types of tumors that might play the 
role in evolution; examples of tumors that have played 
the role in evolution.
The discussion of experimental confirmation of 
nontrivial predictions of the hypothesis will include the 
analysis of evolutionary novelty of tumor-specifically 
expressed EST sequences; ELFNI – AS1, a human 
gene with possible microRNA function expressed 
predominantly in tumors and originated in primates; 
PBOV1, a human gene of the recent de novo origin 
with predicted highly tumor-specific expression profile; 
and the evolutionary novelty of human cancer/testis 
antigen genes.
The conclusion is made that expression of protogenes, 
evolutionarily young and/or novel genes in 
tumors might be a new biological phenomenon, a 
phenomenon of TSEEN (Tumor Specifically Expressed, 
Evolutionarily New) genes, predicted by the hypothesis 
of evolution by tumor neofunctionalization.
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HIV and metabolic disease: Clues to control 
of HIV infection from the immune and 
virological response to high dose Vitamin D 
challenge  
Barry Peters
Kings College London, UK
Effective use of HAART markedly reduces morbidity 
and mortality due to classical HIV disease. The 4 
key emerging diseases in people with HIV that are 
amenable to prevention & therapy are Coronary Heart 
Disease, Renal Disease, Fragility Fractures, Diabetes.
These constitute an increasing burden of morbidity 
and mortality in HIV uninfected people due to an aging 
population and are becoming even more prevalent in 
people with chronic HIV. 
The issue is exemplified by fragility fractures, a major 
cause of mortality in the elderly, and emerging as a 
manifestation occurring earlier in people with HIV, and 
increasing in incidence.
The Probono Study from Kings College London 
demonstrated among 222 patients with matched 
controls that reported fractures at any site during 
adulthood occurred more frequently in HIV than 
controls, 45 (20.3%) vs. 16 (7.2%)  (OR=3.27; 
p=0.0001). Osteoporosis was more prevalent in HIV 
(17.6% vs. 3.6%, p<0.0001). In HIV, use of highly 
active antiretroviral therapy (HAART), low body mass 
and serum PTH were significantly related to low BMD in 
multivariate analysis.
The changing patterns of morbidity and mortality 
in HIV, driven by the metabolic consequences of 
HIV infection itself, and the HAART therapy requires 
development of an appropriate screening and 
management response. 
157
Pathogenesis of Epstein-Barr Virus-driven 
lymphomas of HIV+ patients: new insights 
of potential clinical relevance 
Riccardo Dolcetti
C.R.O. – IRCCS, National Cancer Institute, IT
Human Immunodeficiency Virus (HIV)+ patients have 
an increased risk to develop lymphomas, including 
a significant fraction of histotypes associated with 
Epstein-Barr Virus (EBV) infection. Although restoration 
of EBV-specific T-cell function induced by HAART has 
led to a decreased incidence of the more immunogenic 
EBV-associated lymphomas, such as immunoblastic 
and primary central nervous system lymphomas, other 
EBV+ histotypes are still prevalent in the HAART era, 
particularly Hodgkin’s lymphoma. Therefore, factors 
other than HIV-induced immune suppression are 
probably required for the development of EBV-related 
lymphomas in this setting. Particular attention is being 
given to the identification of microenvironmental 
stimuli able to up-regulate critical EBV latency proteins 
or to induce/enhance EBV replication. In fact, recent 
evidence indicates that, although latency programs 
predominate in EBV-driven tumors, lytic EBV replication 
may also be of pathogenic relevance, at least in the 
early phases of cell transformation. This is particularly 
relevant for HIV-related lymphomagenesis since the 
underlying impairment of immune responses may 
favour uncontrolled activation of EBV lytic replication in 
latently-infected B lymphocytes. Available data indicate 
that local expression of distinct cytokines, including IL-4 
and IL-13, may up-regulate the expression of the LMP-1 
oncoprotein in B cells, thus favoring lymphomagenesis. 
In the search of microenvironmental factors that may 
promote the development of EBV-driven lymphomas 
in HIV+ patients, we obtained evidence supporting 
a pathogenic role for HIV matrix protein p17, which 
accumulates in lymphoid tissues of HIV+ individuals, 
even during HAART. Our findings support a direct 
contribution of HIV p17 to the development of EBV-
driven lymphomagenesis and may provide the rationale 
for new strategies of clinical intervention in this setting.
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Hepatitis C Treatment Update: Current 
Status and Future Direcctions
Shyam Kottilil
National Institute of Allergy and Infectious Diseases, 
NIH, US
Hepatitis C virus infection is a major cause of liver 
disease, with170 million persons infected worldwide. 
Hepatitis C virus is a ssRNA virus that preferentially 
infects human hepatocytes. Approximately 80% of HCV 
infections progress to chronicity, with development 
of hepatic fibrosis over time with 20% developing 
cirrhosis within 25 years, and 20% of these developing 
hepatocellular carcinoma. HCV remains the primary 
cause of liver transplantation worldwide. Of the 1 
million people infected with HIV in the United States, 
about a third are co-infected with HCV. While cART 
has dramatically decreased the number of AIDS-related 
opportunistic infections, HCV- related liver disease has 
become leading cause of death in this population. 
HIV/HCV coinfected individuals have an accelerated 
progression of liver disease and lower therapeutic 
response rates when compared to their HCV mono-
infected counterparts.  In light of the higher rates of 
adverse events observed with current treatment in 
HIV/HCV coinfected patients, there remains a need for 
therapies with improved response rates, convenient 
dosing schedules, and safety profiles. Currently, the 
field of HCV therapeutics is evolving to rapidly develop 
strategies that are highly safe and efficacious for the 
eradication of HCV without the use of interferon 
formulations. Directly acting antivirals that target 
various stages of the HCV life cycle are being developed 
and will likely revolutionize the management of 
HCV by simplifying treatment, improving tolerability 
of regimens, and decreasing duration of therapy 
while maintaining or increasing rates of SVR. This 
presentation will discuss the newer therapeutics that are 
being developed for treating hepatitis C in HIV-infected 
subjects.
159
Hepatitis B Treatment Update: Current 
Status and Future Directions 
Rohit Talwani
Institute of Human Virology, US
The current standard of care for chronic hepatitis B 
infections entails use of nucleoside/nucleotide analogue 
reverse transcriptase inhibitors or pegylated interferon. 
The presentation will:
•	Provide	an	overview	of	the	current	standard		 	
   of care for treatment of chronic HBV in patients    
   with and without HIV co-infection including a    
   review of treatment endpoints in chronic 
   HBV infection 
•	Explore	future	directions	of	HBV	treatment	including	
   an evaluation of strategies geared toward attaining a 
   functional cure of chronic HBV infection
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Treatment Strategies to Minimize the 
Impact of Antiretroviral Drug Toxicities
Bruce Gilliam
Institute of Human Virology, US
Treatment success with antiretroviral drug regimens 
continues to improve.  However, as HIV infected 
patients live longer, the clinician and patient are 
challenged with managing the complications of 
numerous co-morbidities and drug toxicities.  While 
some of these problems may not be able to be 
prevented, the availability of multiple new antiretroviral 
agents now gives the clinician and patient multiple 
options to achieve virologic suppression.  This raises 
the question of which combinations of antiretroviral 
agents have optimal safety and toxicity profiles for the 
individual patient.  The potential implications of the 
choice and usage of certain antiretroviral agents and 
regimens and their known and potential advantages 
and disadvantages/toxicities will be reviewed and the 
avenues for further investigation will be highlighted.    
The complexities of managing an HIV infected patient 
today, including co-morbidities and antiretroviral drug 
toxicities, suggest that newer treatment strategies 
which reevaluate the factors and considerations that 
influence how antiretroviral agents and regimens 
are chosen may well move away from the currently 
recommended regimens in the future to attain the goal 
of minimization of long-term antiretroviral toxicities.
 
 
 
 
 
 
 
 
161
Anti-tuberculosis Treatment for HIV-positive 
Patients in Moscow 
E.M.Bogorodskaya
Moscow City Research and Practical Centre for 
Tuberculosis Control
No abstract provided.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abstracts15th Annual International Meeting of the Institute of Human Virology 70
INTERNATIONAL MEETING
1
5
T
H
 
A
N
N
U
A
L
Institute of Human Virology in partnership with 
the Global Virus Network and The Moscow 
Center for HIV/AIDS Prevention and Treatment
SEPTEMBER 8 –12, 2013  |  MOSCOW
CONTENTS SPEAKER SCHEDULE EVENTS SCHEDULE
1
5
T
H
 
A
N
N
U
A
L
ABSTRACTS INDEX
162
Challenges Fueling the Complexities of TB 
Diagnosis & TBHIV Comorbidity in  
Tanzania- IHV experience
Abubakar Maghimbi, MD, Mtebe Majigo, MD, 
Vincent Mashinji, MD, George Loy, MD, Sekela 
Mwakyusa MD 
Institute of Human Virology, University of Maryland 
School of Medicine (TZ) 
Background: Tanzania with a population of 44.9 million is 
classified as one of the 22 high burden countries for tuberculosis 
(TB). The country houses 5,972 health facilities; the majority 
in urban areas while rural areas have limited access to TB 
diagnostic services. The TB notification rate for all cases in 2011 
was 153/100,000 people with 59/100,000 being smear positive. 
Nevertheless, the 2013 National TB prevalence survey revealed 
prevalence of bacteriological confirmed TB was 354/100,000 
with the rural areas more affected. The findings signify more 
TB than reported. TB continues to major driver of mortality in 
HIV patients, as reported by facilities supported by IHV, with 
the highest mortality in our HIV project.  20% died while on TB 
treatment and 73% died with symptoms of TB. Challenges: 
IHV’s program reports a low rate of TB among HIV patients. 
By June 2013, 20 districts treated 35,502 HIV patients, with 
only 1% diagnosed with TB; almost half being from 4 districts 
with the TB intervention project. The result is likely due to 
insufficient diagnostic services. In some areas, patients travel 
100km to access services. More refined diagnostic techniques to 
increase sensitivity like LED Microscopy, molecular technology, 
and sputum culture are insufficient which poses particular 
challenges for HIV/AIDS patients. TB detection activities 
have primarily remained health facility based endeavors with 
minimal community involvement. These circumstances do 
not provide for an optimal environment for increased TB case 
detection and hence hinders TB control efforts. Interventions: 
IHV implements a WHO funded TB program in Tanzania to 
support active intensified case management which has led to 
finding more TB cases, with 38% of all forms of TB, and 36% 
Smear and/or bacteriological positive. Our challenge was the 
inadequacy of sensitive diagnostic facilities, and hence installed 
one GeneXpert machine which registered an increase of 6.6% 
TB cases that were missed by fluorescent microscopy. Building 
on experience gained and lessons learned, IHV plans to impact 
case detection through  the installation of 4 more GeneXpert 
machines at high prevalence sites which have limited access to 
diagnosis. 
Conclusion and Recommendation: Health systems 
strengthening for laboratory diagnosis and empowering 
community case identification can result in a marked increase 
in TB case finding. With the multidrug-resistant Mycobacterium 
tuberculosis emerging at an alarming rate, support is required 
to identify and detect suspected cases, improve diagnostic 
capacity with efficient technology, and improve linkage between 
diagnostic centers and treatment facilities.
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HIV and kidney function with a focus on 
traditional risk factors and role of TDF, PI 
and other medication 
Patrick Mallon
UCD School of Medicine and Medical Science, IE
No abstract provided.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 